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CHAPTER 1. GENERAL INTRODUCTION 
 
The structure of the female breast is remarkable for its physiological function for 
lactation, and consists of muscular, lymphatic, connective, adipose, and epithelial 
tissues. On top of the pectoralis muscle and ribcage, the breast is situated between the 
edge of the sternum across to the center of the axilla. The breast is uniquely comprised 
of lobules, which collectively form the lobes of the breast – and produce milk for 
lactation in females. Milk ducts connect lobules and lobes of the breast to serve as a 
transport system for milk to the nipple (Figure 1). Fibrous connective and adipose 
tissues account for the majority of the breast mass, and are where ducts and lobules 
are spread throughout in the breast. Within adipose/fat tissues, a complex network of 
nerves, lymphatic vessels and nodes, blood vessels, ligaments and fibrous connective 
tissues serve to distribute elements throughout the body through the circulatory and 
lymphatic systems. 
Breast cancer arises from uncontrolled cell proliferation in the breast, usually in 
the cells of lobules and terminal ducts, and is the most common cancer among women 
worldwide.6 In the United States, breast cancer ranks as the most commonly diagnosed 
malignancy among women, accounting for 29.2% of all newly diagnosed cancers and 
14.4% of female cancer deaths annually (Figure 2).7,8 Breast cancer is a phenotypically 
diverse disease and consists of tumors with various molecular and pathologic 
characteristics, which are determinants for metastatic behavior and clinical outcome. 
Breast cancers are classified based on the histopathology of the tumor and extent of 
disease spread, into in situ and invasive types. Ductal carcinoma in situ (DCIS) is 
classified as a non-invasive cancer of the 
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Figure 1. Microscopic view of normal breast tissue. Magnification: 100X. Photograph courtesy of E. Abdulfatah, 
Wayne State University, Department of Pathology. 
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Estimated new cancer cases among females, 2016. 
Cancer site N % 
Breast         246,660  29.2% 
Lung and bronchus         106,470  12.6% 
Colon and rectum           63,670  7.5% 
Uterine corpus           60,050  7.1% 
Thyroid           49,350  5.8% 
Non-Hodgkin lymphoma           32,410  3.8% 
Melanoma of the skin           29,510  3.5% 
Leukemia           26,050  3.1% 
Pancreas           25,400  3.0% 
Kidney and renal pelvis           23,050  2.7% 
All sites         843,820  100% 
   
   Estimated cancer deaths among females, 2016. 
 Cancer site N % 
Lung and bronchus           72,160  25.6% 
Breast           40,450  14.4% 
Colon and rectum           23,170  8.2% 
Pancreas           20,330  7.2% 
Ovary           14,240  5.1% 
Uterine corpus           10,470  3.7% 
Leukemia           10,270  3.6% 
Liver and intrahepatic bile duct             8,890  3.2% 
Non-Hodgkin lymphoma             8,630  3.1% 
Brain and other nervous system             6,610  2.3% 
All sites         281,400  100% 
Figure 2. Leading cancer types for estimated new cancer cases and cancer 
deaths among females in the United States, 2016. Cases are rounded to the 
nearest ten and excludes basal cell and squamous cell skin cancers and in situ 
carcinoma except urinary bladder.7  
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breast, where cells of the breast ducts have morphed abnormally into cancer cells. 
Unique to this type of breast cancer, these abnormal cells have not invaded through 
ductal walls into surrounding tissue of the breast and have low potential to spread 
(Figure 3A).6 In contrast, the majority of diagnosed breast cancers are of the invasive 
type, where cancer cells have infiltrated through glandular or ductal walls into 
surrounding breast tissue (Figure 3B). Invasive breast cancers are clinically staged to 
determine the extent of disease spread throughout the primary site and regional lymph 
nodes, and the presence of cancer in distant organs. Clinical staging of breast cancer 
dictates clinical therapy regimens and patient prognosis.6 
National Comprehensive Care Network (NCCN) guidelines for the treatment of 
invasive breast cancer outline systemic adjuvant therapies based on hormone receptor 
(HR) and human epidermal growth factor receptor 2 (HER2) statuses, where positive 
HR status is defined as expression of the estrogen (ER) and/or progesterone (PR) 
receptors.9 Clinically, tumor cells are evaluated for these biological markers to 
approximate cancer molecular subtype based on expression profiling (Luminal A/B, 
HER2-enriched, basal). These molecular characteristics dictate course of treatment and 
therapies for patients. Thus, there is a critical need to understand the genetic and 
epigenetic abnormalities that are associated with the different types of breast cancer for 
the development of novel therapies. 
Luminal breast cancers account for about 60% of all cases, are hormone 
receptor-positive (HR+), and can be classified based on HER2 status.10 Luminal A 
breast cancers are HER2-negative (HR+/HER2-) and include ER+/PR+, ER+/PR-, and 
ER-/PR+ status. Their adjuvant treatment includes endocrine therapy with or without 
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Figure 3. Microscopic view of (A) ductal carcinoma in situ and (B) invasive ductal breast cancer tissues. Magnification: 
100X. Photographs courtesy of E. Abdulfatah, Wayne State University, Department of Pathology. 
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multimodality chemotherapy, based on tumor size, lymph node status, and, more 
recently, the 21-gene recurrence score.9 Luminal A breast cancers are associated with 
the most favorable short-term prognosis due to favorable responses to endocrine 
therapy.11,12 However, assessment of long-term prognosis demonstrates similar or 
worse overall survival for Luminal A cases as compared to other subtypes.13 
Luminal B tumors tend to be more aggressive, demonstrate HER2-enrichment 
(HR+/HER2+), and encompass ER+/PR+, ER+/PR-, and ER-/PR+ cases. 
Recommended treatment for Luminal B tumors includes anthracycline-based 
multimodality chemotherapy containing trastuzumab, followed by a one-year course of 
trastuzumab and five years of endocrine therapy.9 Together, Luminal breast cancer 
subtypes are associated with the best short-term prognoses for patients, attributable to 
favorable responses to hormonal therapy.11,12 
Clinical differences among Luminal breast cancers can be attributed to the 
opposing effects of estrogen and progesterone on tumor progression. Estrogen 
supports tumor growth but suppresses progression, whereas progesterone supports 
tumor progression and is associated with more aggressive disease.14 In the absence of 
estrogen signaling (ER- tumors), high progesterone levels in women have been shown 
to support tumor progression without opposition from estrogen.15,16  
The most aggressive subtype of breast cancer is basal-like, where aberrant 
tumor cells are generally triple-negative, meaning estrogen receptor (ER)-negative, 
progesterone receptor (PR)-negative, and lacking human epidermal growth factor 
receptor 2 (HER2/ERBB2)-enrichment.17,18 Basal-like tumors are associated with higher 
rates of metastasis and death, and the treatment for basal breast cancer consists of 
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standard chemotherapy regimens as no effective molecularly-targeted therapies have 
been developed. 
Taken together, breast cancer is a disease consisting of over twenty histological 
subtypes and four molecular subtypes.19 Unique presentations of these subtypes, in 
combination with variable risk factors of disease, make this heterogeneous disease 
more challenging to treat and profile for patients.20 Thus, there is a critical need to 
develop a better understanding of the disease risks and disparities, as well as a better 
understanding of aggressive breast cancer subtypes, particularly among high risk 
populations, to ultimately yield novel discoveries that will impact clinical therapies and 
improve survival outcomes of patients. 
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CHAPTER 2. DISPARITIES AMONG FEMALE PATIENTS DIAGNOSED  
WITH BREAST CANCER 
 
INTRODUCTION 
 
Racial/ethnic disparities in breast cancer incidence and survival 
Among breast cancer cases, racial/ethnic disparities persist, where higher 
incidence rates are observed among whites than blacks (128.1 versus 124.3 per 
100,000, respectively) aged 45 years and older at diagnosis, although recent data 
suggest these rates are converging.7 Some of this disparity can be attributed to 
differences in clinical characteristics, such that black women tend to be 
disproportionately diagnosed with early-onset disease (age < 35 years at diagnosis) and 
with more aggressive tumors.7,21,22 Indeed, previous studies have demonstrated that 
among Luminal A tumors, race-associated biological factors contribute to poorer 
outcomes in blacks compared to white women.23,24 
While overall age-adjusted breast cancer mortality has declined significantly 
since 1990, racial disparities have widened, as black women suffer from approximately 
42% higher mortality rates compared to white or Hispanic women.8,21,25 Differences in 
the uptake of cancer screening and access to high-quality treatment have also been 
suggested as contributory factors to racial disparities in breast cancer mortality, even in 
early-stage disease.26-29 Population-based studies have reported that pre-menopausal 
black women under 50 years of age have approximately 1.5-fold higher incidence of 
triple negative breast cancers and poorer survival outcomes, partly attributed to limited 
systemic treatment options for this aggressive breast cancer subtype.17,30-32  
Geographic variations also contribute to racial and ethnic disparities in breast 
cancer incidence and mortality. Among black women as represented by 18 
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Surveillance, Epidemiology, and End Results (SEER) program registries across the 
United States, age-adjusted incidence for in situ female breast cancer rates per 100,000 
females are 31.54 and 31.02 for whites and blacks, respectively (Figure 4A). Rates in 
Detroit for female in situ breast cancers are higher, however, at 36.73 and 36.05 cases 
per 100,000 white and black females, respectively. This disparity persists among 
invasive breast cancers for females, as national rates of invasive breast cancer per 
100,000 females are 127.96 and 125.19 for whites and blacks, respectively. In Detroit, 
incidence rates are 133.06 and 131.31 for white and black females (Figure 4B). This 
disparity in incidence rates for in situ and invasive breast cancers among white and 
black women in Detroit versus the United States demonstrate a unique population that 
needs to be further investigated to understand the etiology and development of tumors 
in this population. Further, the disparities observed between white and black women 
nationally are paralleled in Detroit and are consistent with prior studies that examine 
racial and ethnic disparities in breast cancer incidence and mortality. 
 
Age at breast cancer diagnosis and familial history of breast cancer 
Nearly 7% of all breast cancer cases in women are diagnosed before the age of 
40 years,33 and among women 20 to 39 years of age, breast cancer still ranks as the 
leading cause of cancer death. Women diagnosed with breast cancer at a young age 
tend to present with higher grade, hormone-insensitive tumors with more frequent 
spread to regional lymph nodes compared to older patients.34 It is also established that 
patients age < 35 years whose surgical treatment consists of breast-conserving surgery 
and radiation have a greater risk of local recurrence at ten years compared to patients
10 
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Figure 4. Age-adjusted Surveillance, Epidemiology, and End Results (SEER) incidence 
rates per 100,000 females for (A) in situ and (B) invasive breast cancer by registry and 
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who opt for a mastectomy.35 Further, women under 40 years of age at diagnosis are 
more likely to undergo mastectomy for breast cancer treatment compared to older 
women.36,37 Independent of stage, histology, and extent of disease at breast cancer 
diagnosis, women under 40 years of age diagnosed with AJCC clinical stage I-II breast 
cancer have a lower rate of survival.34,38-41 Young women with breast cancer also tend 
to consider consequences of treatment with regard to premature menopause, body 
image, fertility, and risk of secondary cancers.42,43 
Young-onset breast cancer has also been shown to be associated with an 
increased familial risk of disease. Lalloo et al. reported that among thirty-seven women 
with strong family history of breast cancer diagnosed at age < 30 years, about half 
harbored a BRCA mutation.44 By race, Churpek et al. observed that one in four women 
had a BRCA mutation among black patients with young-onset disease, a familial history 
of breast cancer, or triple-negative breast cancer.45 BRCA mutation frequencies were 
also reported to be higher among black women, compared to whites, in a population-
based Florida study of 396 women.46 While heritable mutation frequencies may be 
higher among black women, reports have revealed that black women have a lower 
uptake of genetic testing services compared to whites.47-50 
 
Menopausal and socioeconomic status on breast cancer risk and outcomes 
Early menarche and late menopause are also health factors that contribute to 
breast cancer risk.51 Progesterone levels are higher in pre-menopausal women, typically 
those diagnosed with breast cancer under the age of 50, compared to post-menopausal 
women over age 60.52,53 Thus, post-menopausal women who naturally circulate high 
12 
	
 
 
levels of endogenous sex hormones have increased risk of breast cancer development 
compared to counterparts with low hormone levels.54  
Access to screening, genetic testing, high-quality treatment, and delays in 
surgical care has also previously been attributed to disparities in breast cancer 
mortality.27,28 Insurance status has also been shown to be a strong risk factor for poor 
outcomes among adolescents and young adults, particularly among tumor types that 
are responsive to early detection.55 Differences in access to high-quality cancer care 
may contribute to disparities in breast cancer diagnosis and treatment. 
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RESULTS:  
 
DISPARITIES IN SURGICAL THERAPY AMONG FEMALE PATIENTS  
WITH YOUNG ONSET EARLY-STAGE BREAST CANCER 
 
Description of study cohort 
 
The purpose of the study was to compare uptake of surgical therapy, specifically 
breast-conserving surgery (BCS), versus mastectomy among non-Hispanic white 
(NHW), non-Hispanic black (NHB), and Hispanic women under 40 years of age 
diagnosed with AJCC clinical stage I-II breast cancer, the majority of whom are treated 
first with surgery. A total of 6,449 incident early-stage breast cancer cases diagnosed in 
women age <40 years were identified from the Surveillance, Epidemiology, and End 
Results (SEER) database with race categorized as NHW, NHB, and Hispanic (4,013 
NHW; 1,059 NHB; 1,377 Hispanic) who underwent surgical treatment from 2010 
through 2013 (Figure 5). 10.7% of these young-onset breast cancer cases were 
diagnosed before the age of 30 (690 of 6,449 cases), and NHB women were diagnosed 
younger than NHWs and Hispanics (p-value = 0.002 and 0.0324, respectively) (Figure 
5). NHW patients were more likely to be insured as compared to NHB or Hispanics 
(86.2% vs 69.4% and 66.2%, respectively; p-value = <0.0001 and <0.0001, 
respectively). 
Consistent with previous reports,17,31,32 triple negative breast cancers were 
significantly more frequent among NHBs compared to NHWs and Hispanics (26.6% vs 
17.8% and 22.3%, respectively; p-value = <0.0001 and 0.002, respectively) (Figure 5). 
Also consistent with previous reports,56-59 NHW and Hispanic patients tended to present 
with smaller primary tumors (p-value = 0.0004 and 0.0315, respectively) as well 
14 
	
 
 
 
  NH White NH Black Hispanic   p-value* 
  N % N % N %   NHW:NHB NHW:H NHB:H 
Total 4013  1059  1377      
Age at Diagnosis       0.002 0.7237 0.0324 
<25 56 1.40% 18 1.70% 22 1.60%     
25-29 352 8.80% 109 10.30% 133 9.70%     
30-34 1087 27.10% 336 31.70% 368 26.70%     
35-39 2518 62.70% 596 56.30% 854 62.00%     
Mean (std) 34.9 (3.8) 34.5 (3.9) 34.7 (3.8)     
Subtype        <0.0001 0.002 0.0844 
HR+/HER2- 2163 53.90% 511 48.30% 720 52.30%     
HR+/HER2+ 696 17.30% 159 15.00% 207 15.00%     
HR-/HER2+ 231 5.80% 56 5.30% 76 5.50%     
HR-/HER2- 714 17.80% 282 26.60% 307 22.30%     
Unknown 209 5.20% 51 4.80% 67 4.90%     
AJCC Clinical Stage       <0.0001 <0.0001 0.4038 
IA 1587 39.50% 317 29.90% 426 30.90%     
IB 145 3.60% 35 3.30% 33 2.40%     
IIA 1341 33.40% 429 40.50% 535 38.90%     
IIB 940 23.40% 278 26.30% 383 27.80%     
Tumor Grade       <0.0001 <0.0001 0.5007 
I (Well differentiated) 412 10.30% 67 6.30% 102 7.40%     II (Moderately 
differentiated) 1398 34.80% 308 29.10% 429 31.20%     
III (Poorly differentiated) 2028 50.50% 619 58.50% 774 56.20%     
IV (Undifferentiated) 15 0.40% 7 0.70% 10 0.70%     
Unknown 160 4.00% 58 5.50% 62 4.50%     Tumor Sizea        0.0004 0.3839 0.0315 
≤5.0 cm 3900 97.20% 1006 95.00% 1329 96.50%     
>5.0 cm 113 2.80% 53 5.00% 45 3.30%     
Nodal Involvement       0.4047 0.0559 0.452 
No 2598 64.70% 671 63.40% 852 61.90%     
Yes 1415 35.30% 388 36.60% 525 38.10%     
Insurance        <0.0001 <0.0001 0.0186 
Insured 3459 86.20% 735 69.40% 912 66.20%     
Uninsured 90 2.20% 43 4.10% 90 6.50%     
Medicaid 407 10.10% 262 24.70% 358 26.00%     
Unknown 57 1.40% 19 1.80% 17 1.20%         
*p-value calculations do not include unknown values.         
NHW:NHB = Non-Hispanic White:Non-Hispanic Black         
NHW:H = Non-Hispanic White: Hispanic 
 	 	 	 	 	 	 	 	NHB:H = Non-Hispanic Black: Hispanic  	 	 	 	 	 	 	 	a3 patients had unknown tumor size.  	 	 	 	 	 	 	 	
Figure 5. Summary of clinicodemographic characteristics by race/ethnicity among women diagnosed with young-onset 
early-stage breast cancer; Surveillance, Epidemiology, and End Results (SEER) 18, 2010-2013. 
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  NH White NH Black Hispanic   p-value* 
  N % N % N %   NHW:NHB NHW:H NHB:H 
Total 4013  1059  1377      
Surgical Therapyb       <0.0001 0.0042 0.2244 
BCS 1251 31.20% 399 37.70% 487 35.40%     
Mastectomy 2757 68.70% 657 62.00% 889 64.60%     
Radiation Therapy       0.0374 0.9256 0.0671 
No 2194 54.70% 531 50.10% 755 54.80%     
Yes 1608 40.10% 452 42.70% 550 39.90%     
Unknown 211 5.30% 76 7.20% 72 5.20%     
BCS and Radiation°       0.0076 <0.0001 0.165 
BCS only 277 22.10% 110 27.60% 160 32.90%     
BCS and Radiation  898 71.80% 250 62.70% 295 60.60%     
Unknown 76 6.10% 39 9.80% 32 6.60%     
Mastectomy and Radiation°      0.0059 0.0923 0.298 
Mastectomy only 1914 69.40% 418 63.60% 594 66.80%     
Mastectomy and Radiation 710 25.80% 202 30.70% 255 28.70%     
Unknown 133 4.80% 37 5.60% 40 4.50%         
*p-value calculations do not include unknown values. 
	 	 	 	 	 	 	 	NHW:NHB = Non-Hispanic White:Non-Hispanic Black 
	 	 	 	 	 	 	 	NHW:H = Non-Hispanic White: Hispanic 
 	 	 	 	 	 	 	 	NHB:H = Non-Hispanic Black: Hispanic 
 
	 	 	 	 	 	 	 	BCS: Breast-conserving surgery/lumpectomy.  	 	 	 	 	 	 	 	
b9 patients had unknown information on type of surgical therapy. 
	 	 	 	 	 	 	°Among individuals who had BCS or mastectomy, respectively. 
	 	 	 	 	 	 	
Figure 6. Summary of treatment characteristics by race/ethnicity among women diagnosed with young-onset early-
stage breast cancer; Surveillance, Epidemiology, and End Results (SEER) 18, 2010-2013. 
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as lower grade tumors (p-value < 0.0001 and 0.0001, respectively) compared to NHB 
women (Figure 5). No significant differences were observed by race/ethnicity for lymph 
node involvement. 
In terms of surgical therapy, both NHBs and Hispanics were significantly less 
likely to undergo mastectomy than NHW women (p-value = <0.0001 and 0.0042, 
respectively) (Figure 6). NHB patients were significantly more likely to undergo radiation 
treatment compared to NHWs (p-value = 0.0374). To further assess racial differences in 
therapeutic uptake, receipt of radiation therapy was evaluated among each surgical 
type. As presented in Figure 6, among women who received BCS, NHWs were 
significantly more likely to receive radiation as compared to NHBs and Hispanics (p-
value = 0.0076 and <0.0001, respectively). In contrast, among women who underwent 
mastectomy, NHWs were significantly less likely than NHB to undergo radiation (p-value 
= 0.0059). Further stratification by stage at diagnosis demonstrated that among NHBs 
who underwent a mastectomy, 69.1% were diagnosed at stage II versus only 58.8% of 
NHW patients with stage II disease (p = <0.0001, data not shown). No significant 
differences were observed with Hispanic women.  
 
Racial/ethnic disparities in receipt of surgical therapy 
Odds ratios (OR) for receipt of mastectomy, adjusted for age, race/ethnicity, 
insurance status, subtype, stage, tumor size, lymph node involvement, and radiation 
therapy, are presented in Figure 7. NHB and Hispanic women were 24% and 21% less 
likely to undergo a mastectomy compared to NHW women (OR 0.76, 95% CI 0.63-0.90; 
OR 0.79, 95% CI 0.67-0.92; respectively). No significant differences in surgical therapy 
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were observed by breast cancer subtype. Compared to women aged 35 to 39 years, 
those diagnosed at younger ages were 1.33 to 2.23-fold more likely to have a 
mastectomy. Uninsured women were 23% less likely to undergo a surgical mastectomy 
(OR 0.77, 95% CI 0.65-0.92). 
Stratification of cases by tumor subtype (using NHW cases as the referent) 
revealed that NHB and Hispanic individuals were less likely to undergo a mastectomy 
among all subtypes (Figure 8). NHB and Hispanic women were 65% and 50% less likely 
to undergo a mastectomy among women with HER2-enriched tumors, compared to 
NHW (OR 0.35, 95% CI 0.17-0.71; and OR 0.50, 95% CI 0.26-0.94, respectively). 
Significant differences were also observed between Hispanic and NHW women 
diagnosed with Luminal A (HR+/HER2-) tumors (OR 0.77, 95% CI 0.62-0.96). Among 
patients diagnosed with Luminal A (HR+/HER2-) and triple negative (HR-/HER2-) 
tumors, younger age was significantly associated with an increased likelihood to 
undergo a surgical mastectomy compared to BCS (Figure 8). By stage, women with 
AJCC stage II tumors were significantly more likely to undergo a mastectomy compared 
to stage I cases among Luminal A tumors (OR 1.63, 95% CI 1.31-2.01).
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  Mastectomy§* 
  OR (95% CI) p-value 
Race/Ethnicity 
  Non-Hispanic White Ref 
 Non-Hispanic Black 0.76 (0.63-0.90) 0.0019 
Hispanic 0.79 (0.67-0.92) 0.0037 
Age at Diagnosis 
  <25 2.23 (1.27-3.90) 0.0051 
25-29 1.44 (1.15-1.82) 0.0019 
30-34 1.33 (1.15-1.55) 0.0001 
35-39 Ref 
 Subtype 
  HR+/HER2- Ref 
 HR+/HER2+ 0.99 (0.84-1.18) 0.9471 
HR-/HER2+ 1.21 (0.91-1.60) 0.1825 
HR-/HER2- 0.89 (0.75-1.04) 0.1416 
AJCC Clinical Stage   
I Ref  
II 1.33 (1.14-1.55) 0.0003 
Insurance 
  Insured Ref 
 Medicaid 1.24 (0.87-1.78) 0.2372 
Uninsured 0.77 (0.65-0.92) 0.0037 
*Model adjusted for race/ethnicity (NH White, NH Black, Hispanic), 
age at diagnosis (5 year groups), clinical subtype (Luminal A/B, 
HER2, Triple negative), stage (I/II), tumor size (≤5.0 cm versus >5.0 
cm), nodal involvement (yes/no), radiation therapy (yes/no), insurance 
(insured, Medicaid, uninsured).  
§Referent group is patients who received breast-conserving surgery. 
Figure 7. Adjusted odds ratios for early-stage breast cancer 
patient clinicodemographic characteristics, SEER 18, 2010-2013. 
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Mastectomy§* 
 
HR+/HER2- 
 
HR+/HER2+ 
 
HR-/HER2+ 
 
HR-/HER2- 
  OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value 
Age at Diagnosis            
<25 4.17 (1.68-10.34) 0.002  1.71 (0.61-4.78) 0.304  5.28 (0.52-53.73) 0.16  0.63 (0.19-2.12) 0.4545 
25-29 1.57 (1.13-2.19) 0.0078  1.39 (0.84-2.32) 0.2035  0.80 (0.32-2.01) 0.6374  1.52 (0.94-2.46) 0.086 
30-34 1.30 (1.06-1.59) 0.0115  1.23 (0.86-1.76) 0.2505  0.95 (0.52-1.73) 0.8729  1.64 (1.21-2.23) 0.0015 
35-39 Ref   Ref   Ref   Ref  
Race/Ethnicity            
Non-Hispanic White Ref   Ref   Ref   Ref  
Non-Hispanic Black 0.88 (0.68-1.14) 0.3407  0.65 (0.43-1.00) 0.051  0.35 (0.17-0.71) 0.0033  0.77 (0.54-1.08) 0.1261 
Hispanic 0.77 (0.62-0.96) 0.022  0.70 (0.47-1.04) 0.0766  0.50 (0.26-0.94) 0.0323  0.96 (0.68-1.35) 0.797 
AJCC Clinical Stage            
I Ref   Ref   Ref   Ref  
II 1.63 (1.31-2.01) <0.0001  1.01 (0.69-1.47) 0.9698  1.07 (0.57-2.00) 0.8303  1.01 (0.73-1.41) 0.9362 
*Model adjusted for race/ethnicity (NH White, NH Black, Hispanic), age at diagnosis (5 year groups), stage (I/II), tumor size (≤5.0 cm versus >5.0 cm), 
nodal involvement (yes/no), radiation therapy (yes/no), and insurance (insured, Medicaid, uninsured).  
§Referent group is patients who received breast-conserving surgery. 
Figure 8. Adjusted odds ratios for early-stage breast cancer patient clinicodemographic characteristics by subtype, SEER 18, 
2010-2013. 
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RESULTS:  
 
HER2 STATUS AND DISPARITIES IN LUMINAL BREAST CANCERS 
 
Differences among ER+/PR+, ER+/PR-, and ER-/PR+ HR-positive breast cancers 
Expression of the estrogen (ER) and/or progesterone (PR) receptors was defined 
as hormone-receptor positive (HR+) disease.9 To study clinical, demographic and 
socioeconomic differences within Luminal A (HR+/HER2-) and Luminal B (HR+/HER2+) 
clinical breast cancer subtypes, 134,639 patients with HR+ and known HER2 receptor 
status were gathered from the Surveillance, Epidemiology, and End Results (SEER) 
database.60 Among these patients, 118,285 (87.8%) cases were HR+/HER2- (Luminal 
A) (Figure 9), and 16,354 (12.2%) were HR+/HER2+ (Luminal B) tumors (Figure 10).  
For Luminal A (HR+/HER2-) cases, 102,087 (86.3%) were ER+/PR+; 14,994 
(12.7%) ER+/PR-; and 1,204 (1.0%) ER-/PR+ (Figure 9). Luminal A subtype patients 
demonstrated significantly different distributions by age, race/ethnicity, tumor size, 
AJCC clinical stage, and SES measures of poverty (p<0.0001). Specifically, Luminal A 
cases with ER-/PR+ status were more likely to be diagnosed at a younger age, to be 
non-Hispanic (NH) black or Hispanic, to live in counties with higher poverty, to have 
larger tumors, and to present with later stage disease (Figure 9). 
Of the Luminal B (HR+/HER2+) tumors, 11,391 (69.7%) were ER+/PR+; 4,491 
(27.4%) ER+/PR-; and 472 (2.9%) ER-/PR+ (Figure 10). Patients with Luminal B breast 
cancers had distributions that varied by age, race/ethnicity, and AJCC clinical stage. 
Compared with ER+/PR- and ER+/PR+ patients, Luminal B cases with ER-/PR+ status 
were more likely to be diagnosed at a younger age, to be NH Asian, Pacific Islander, or 
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      Luminal A (HER2-)     p-value* 
   ER+ / PR+ ER+ / PR- ER- / PR+  ER+/PR+: ER+/PR+:      
ER+/PR-
:      
  N   N % N % N %   ER+/PR- ER-/PR+ ER-/PR+ 
Total 118,285  102,087  14,994  1,204      
Age at Diagnosis          <0.0001 <0.0001 <0.0001 
<50 21,777  19,299 18.9% 2,081 13.9% 397 33.0%     
50-64 43,550  37,261 36.5% 5,849 39.0% 440 36.5%     
65-74 28,705  24,836 24.3% 3,670 24.5% 199 16.5%     
≥75 24,253  20,691 20.3% 3,394 22.6% 168 14.0%     
Race/Ethnicity          <0.0001 <0.0001 <0.0001 
NH White 85,717  74,701 73.2% 10,297 68.7% 719 59.7%     
NH Black 10,540  8,371 8.2% 1,930 12.9% 239 19.9%     
Asian/Pacific Islander 9,117  7,956 7.8% 1,094 7.3% 67 5.6%     
Am.Indian/AlaskaNative 633  555 0.5% 71 0.5% 7 0.6%     
Hispanic 11,429  9,766 9.6% 1,496 10.0% 167 13.9%     
Unknown 849  738 0.7% 106 0.7% 5 0.4%     
AJCC Stage          <0.0001 <0.0001 <0.0001 
0-I 64,491  57,029 55.9% 7,018 46.8% 444 36.9%     
II 34,905  29,601 29.0% 4,809 32.1% 495 41.1%     
III 11,352  9,329 9.1% 1,868 12.5% 155 12.9%     
IV 4,979  3,997 3.9% 900 6.0% 82 6.8%     
Unknown 2,558  2,131 2.1% 399 2.7% 28 2.3%     
Tumor Size          0.1503 <0.0001 <0.0001 
≤0.5 cm 10,091  8,724 8.5% 1,316 8.8% 51 4.2%     
>0.5 cm 104,379  90,257 88.4% 13,021 86.8% 1,101 91.4%     
Unknown 3,815  3,106 3.0% 657 4.4% 52 4.3%     
Poverty Index          0.0833 <0.0001 <0.0001 
Q1 28,333  24,551 24.0% 3,516 23.4% 266 22.1%     
Q2 27,526  23,778 23.3% 3,513 23.4% 235 19.5%     
Q3 28,566  24,569 24.1% 3,736 24.9% 261 21.7%     
Q4 33,837  29,170 28.6% 4,226 28.2% 441 36.6%     
Unknown 23   19 0.0% 3 0.0% 1 0.1%         
*p-value calculations do not include unknown values. 
Figure 9.	 Patient and tumor characteristics of Luminal A invasive breast cancer cases.4 Summary of clinical and 
demographic characteristics of hormone receptor-positive (HR+), HER2- Luminal A breast cancers in women with invasive 
breast cancer: Surveillance, Epidemiology and End Results 18, 2010-2012. Open access copyright permissions for this article 
permitted re-use of this figure from Cancer Medicine. 
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      Luminal B (HER2+)    p-value* 
   ER+ / PR+ ER+ / PR- ER- / PR+  ER+/PR+: ER+/PR+:      
ER+/PR-
:      
  N   N % N % N %   ER+/PR- ER-/PR+ ER-/PR+ 
Total 16,354  11,391  4,491  472      
Age at Diagnosis          <0.0001 0.7842 <0.0001 
<50 4,621  3,518 30.9% 950 21.2% 153 32.4%     
50-64 6,631  4,431 38.9% 2,016 44.9% 184 39.0%     
65-74 2,886  1,951 17.1% 855 19.0% 80 16.9%     
≥75 2,216  1,491 13.1% 670 14.9% 55 11.7%     
Race/Ethnicity          0.3661 <0.0001 <0.0001 
NH White 10,793  7,545 66.2% 2,970 66.1% 278 58.9%     
NH Black 1,918  1,306 11.5% 555 12.4% 57 12.1%     
Asian/Pacific Islander 1,491  1,038 9.1% 400 8.9% 53 11.2%     
Am.Indian/AlaskaNative 105  63 0.6% 30 0.7% 12 2.5%     
Hispanic 1,921  1,352 11.9% 503 11.2% 66 14.0%     
Unknown 126  87 0.8% 33 0.7% 6 1.3%     
AJCC Stage          <0.0001 <0.0001 0.003 
0-I 6,383  4,534 39.8% 1,710 37.9% 139 29.2%     
II 5,792  4,073 35.8% 1,536 34.2% 183 38.8%     
III 2,463  1,697 14.9% 676 15.1% 90 19.1%     
IV 1,260  781 6.9% 437 9.7% 42 8.9%     
Unknown 456  306 2.7% 132 2.9% 18 3.8%     
Tumor Size          <0.0001 0.1152 0.7848 
≤0.5 cm 1,348  861 7.6% 443 9.9% 44 9.3%     
>0.5 cm 14,178  9,983 87.6% 3,800 84.6% 395 83.7%     
Unknown 828  547 4.8% 248 5.5% 33 7.0%     
Poverty Index          0.1446 0.6807 0.3295 
Q1 3,648  2,514 22.1% 1,025 22.8% 109 23.1%     
Q2 3,717  2,585 22.7% 1,030 22.9% 102 21.6%     
Q3 3,814  2,635 23.1% 1,078 24.0% 101 21.4%     
Q4 5,172  3,654 32.1% 1,358 30.2% 160 33.9%     
Unknown 3  3 0.0% 0 0.0% 0 0.0%     
*p-value calculations do not include unknown values. 
Figure 9.	 Patient and tumor characteristics of Luminal B invasive breast cancer cases.4 Summary of clinical and 
demographic characteristics of hormone receptor-positive (HR+), HER2+ Luminal B breast cancers in women with invasive breast 
cancer: Surveillance, Epidemiology and End Results 18, 2010-2012. Open access copyright permissions for this article permitted 
re-use of this figure from Cancer Medicine. 
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Hispanic, and to be diagnosed at later stages of disease (Figure 10). Among Luminal B 
tumors, no significant differences in SES were observed, measured with census tract 
county-level poverty (p=0.1446, p=0.6807, and p=0.3295, respectively).  
An additional 19,020 breast cancer patients had borderline or unknown status for 
ER, PR, or HER2, and were not included in this analysis. Among these women, 67.7% 
were NH white (12,876 cases), 11.7% were NH black (2,227 cases), 10.9% were 
Hispanic (2,068 cases), 7.4% were Asian or Pacific Islander (1,404 cases), 0.5% were 
American Indian/Alaska Native (91 cases), and 1.9% (354 cases) had unknown 
race/ethnicity (data not shown). 83.0% of unknown cases were diagnosed with invasive 
breast cancer at age 50 years and older (15,793 cases). 61.5% of cases were 
diagnosed with early stage (AJCC stage 0-II) disease (11,701 cases), 17.8% were 
diagnosed with later stage (AJCC stage III-IV) cancer, and 20.1% (3,929 cases) did not 
have information on AJCC stage. 59.1% of cases (11,242 cases) resided in areas 
where at least 31% of residents were living in poverty (Q3 or Q4). Together, cases with 
unknown receptor status tended to be NH white, older, and diagnosed with early stage 
disease (data not shown). 
Overall, it was observed that, regardless of HER2 status, ER-/PR+ cases were 
more likely to be diagnosed in young patients (age < 50 years) and to present with later 
stage (stage III-IV) disease, but were less likely to be non-Hispanic white, as compared 
to ER+/PR- or ER+/PR+ patients.  
 
Socioeconomic disparities in Luminal A breast cancers 
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Significant differences in area-based poverty were also noted among patients 
with Luminal A (HR+/HER2-) tumors. To further explore the relationship of 
socioeconomic status and HR+ status (ER+/PR+, ER+/PR-, or ER-/PR+) within each 
breast cancer subtype, multinomial logistic regression models were used. Because race 
and age are associated with socioeconomic status, analyses were adjusted for these 
variables to determine whether socioeconomic disparities persisted in this population. 
Figure 11 summarizes results from models adjusted for area-based poverty, age, 
and race/ethnicity. Using ER+/PR+ tumors as the referent outcome in each subtype and 
poverty quartile Q1 as the referent covariable, it was found that women with Luminal A 
breast cancer who live in counties with higher poverty were more likely to be diagnosed 
with ER-/PR+ disease (Q4: OR = 1.20, 95% CI = 1.03-1.40) (Figure 11). Women 
diagnosed with ER-/PR+ Luminal A disease were 1.7-fold more likely to under 50 years 
of age compared to women with ER+/PR+ tumors in these area-based poverty-adjusted 
models. In addition, NH blacks were at an increased risk of being diagnosed with ER-
/PR+ Luminal A breast cancers (OR = 2.62, 95% CI = 2.25-3.05) (Figure 11). Notably, 
age, race and poverty were not associated with ER-/PR+ disease in Luminal B breast 
cancers (Figure 11). 
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 Area-Based Poverty
§ 
 Luminal A (HER2-)
◊  Luminal B (HER2+)
₡ 
 ER+ / PR- ER- / PR+  ER+ / PR- ER- / PR+ 
 OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
Age at Diagnosis, years       
<50 0.67 (0.64-0.71) 1.68 (1.47-1.93)  0.59 (0.54-0.65) 1.01 (0.81-1.26) 
50-64* 1 1  1 1 
65-74 0.96 (0.91-1.00) 0.70 (0.59-0.82)  0.97 (0.88-1.07) 0.99 (0.75-1.29) 
≥75 1.08 (1.03-1.13) 0.72 (0.60-0.86)  1.01 (0.90-1.12) 0.94 (0.69-1.28) Race/Ethnicity      
NH White* 1 1  1 1 
NH Black 1.75 (1.66-1.85) 2.62 (2.25-3.05)  1.14 (1.02-1.28) 1.18 (0.88-1.58) 
Asian/Pacific Islander 1.05 (0.98-1.12) 0.77 (0.59-0.99)  1.03 (0.91-1.17) 1.36 (1.00-1.84) 
Am. Indian/Alaska Native 0.96 (0.75-1.23) 1.22 (0.57-2.57)  1.27 (0.82-1.97) 5.15 (2.74-9.67) 
Hispanic 1.19 (1.12-1.26) 1.48 (1.25-1.76)  1.04 (0.93-1.16) 1.31 (0.99-1.73) Poverty Index      
Q1* 1 1  1 1 
Q2 1.02 (0.97-1.07) 0.89 (0.75-1.07)  0.96 (0.87-1.07) 0.90 (0.68-1.19) 
Q3 1.01 (0.96-1.06) 0.88 (0.74-1.05)  0.97 (0.88-1.08) 0.88 (0.66-1.16) 
Q4 0.93 (0.89-0.98) 1.20 (1.03-1.40)  0.88 (0.79-0.97) 0.98 (0.76-1.27) §Model adjusted for age, race, and poverty (quartiles). 
◊Referent group is HER2-/ER+/PR+. 
₡Referent group is HER2+/ER+/PR+. 
*Referent covariable. 
Figure 11.	Adjusted odds ratios for patient demographics and socioeconomic status by hormone receptor-positive (HR+) 
breast cancers.4 Open access copyright permissions for this article permitted re-use of this figure from Cancer Medicine.	
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DISCUSSION 
 
Together, these studies have identified disparities in breast cancer incidence that 
could contribute to differences in survival outcomes for patients at higher-risk of disease 
development. In particular, these studies focused on: (1) racial/ethnic differences in 
surgical treatment among early-stage young onset breast cancers; and (2) associations 
among Luminal breast cancers and socioeconomic status as assessed by age, 
race/ethnicity, and a measurement of county-level poverty and found that within Luminal 
A (HR+/HER2-) and Luminal B (HR+/HER2+) cancers, clinical and demographic 
characteristics varied. 
 
Disparities in surgical therapy among patients with young onset early-stage breast 
cancer 
To minimize known disparities in screening utilization by race/ethnicity,61,62 the 
first study population was restricted to women diagnosed with breast cancer who do not 
undergo routine mammographic screening. This population-based study of early-stage 
breast cancers diagnosed in women aged < 40 years identified age-related, racial, and 
ethnic disparities in uptake of surgical therapy. Both NHBs and Hispanics were less 
likely to undergo a mastectomy among all breast cancer subtypes compared to NHW 
women, with the largest disparities observed among HER2-enriched (HR-/HER2+) 
tumors. 
Regardless of race, younger age at diagnosis was associated with increased 
uptake of mastectomy. Specifically, compared to women aged 35 to 39 years, it was 
observed that women diagnosed at younger ages (20-34 years of age) were 
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significantly more likely to undergo mastectomy regardless of race/ethnicity, consistent 
with surgical trends by age at diagnosis.36,37 Women diagnosed with breast cancer at a 
young age tend to present with higher grade, hormone-insensitive tumors with more 
frequent spread to regional lymph nodes compared to older patients.35 It is also 
established that patients age < 35 whose surgical treatment consists of BCS and 
radiation have a greater risk of local recurrence at ten years compared to patients who 
opt for a mastectomy.35 
Fear of recurrence, avoidance of adjuvant side effects, clinical indicators, and 
perceived favorable survival outcomes have been reported as patient reasons for 
electing surgical mastectomy.63-66 Indeed, the perception that more radical surgery 
results in improved chances of survival persists even though several large multi-
institutional randomized trials have not shown a difference in overall survival between 
patients who undergo breast-conserving surgery and those who undergo mastectomy67-
74 and there is some evidence suggesting that women who undergo breast-conserving 
surgery plus radiation might have a slightly higher breast cancer-specific survival 
rate.75,76 
In the first study, it was observed that NHB patients were significantly more likely 
to undergo radiation therapy, which would be expected in a population significantly 
more likely to undergo BCS than mastectomy as the primary treatment for breast 
cancer. However, the increase in radiation treatment in the NHB is not accounted for by 
differences in mastectomy rate. The differences between NHW and NHB for surgical 
treatment differ by over 5 percent of the population, with larger disparities observed 
among women who underwent breast-conserving surgery. Indeed, these findings are 
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consistent with other studies that indicate NHB women are less likely to receive 
radiation after BCS.77,78 
The focus on early-stage breast cancer cases in women diagnosed < 40 years, 
and examination of subtype-specific differences in uptake of surgery reduced the impact 
that clinical differences may have on patient treatment decisions. Neoadjuvant 
chemotherapy is commonly used prior to surgery for TNBC and HER2+ breast cancer in 
order to facilitate BCS or, in the case of HER2+ tumors, because HER2-targeted 
neoadjuvant chemotherapy regimens containing trastuzumab ± pertuzumab can result 
in high pathologic complete response rates.79,80 Pathologic complete response after 
neoadjuvant chemotherapy is associated with improvements in overall survival and with 
long-term patient outcomes.81,82 While SEER does not capture information on systemic 
therapy, no significant differences were observed by race/ethnicity in the uptake of 
surgical mastectomy among TNBC cases when stratified by subtype. 
The racial/ethnic disparities in surgical therapy that were observed persist even 
after adjustment, as uninsured women were significantly less likely to undergo a 
surgical mastectomy compared to insured patients. Consistent with these observations, 
studies evaluating the cost comparison of mastectomy versus BCS for early-stage 
breast cancer found higher short-term costs but lower long-term costs for BCS than 
mastectomy.83,84 Cost and access to high-quality care could potentially contribute to 
disparities in surgery treatment decisions for breast cancer. While differences in 
exposure profiles (e.g., smoking history), medical history (e.g., menarche, parity, 
obesity), or genetic susceptibility were unavailable for study in SEER, limiting this study 
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population to breast cancers diagnosed in women aged < 40 years allowed for reduction 
of menopausal status as an associated breast cancer risk in this study. 
Patient preferences play a critical role in electing a surgical mastectomy for 
breast cancer, with increased patient involvement in surgery treatment decisions being 
associated with a greater likelihood of mastectomy as the surgical treatment for breast 
cancer.63,85,86 A recent study by Thomas, et al. among invasive breast cancer cases 
across all ages and cancer stage from the National Cancer Data Base (NCDB) noted 
similar findings, with increased rates in utilization of BCS among NHBs.87 This study is 
unique in that the cohort was limited to young-onset (diagnosed at age<40 years) cases 
of early-stage breast cancer where surgery is the primary treatment, and observed that 
NHB and Hispanics were significantly less likely to undergo mastectomy compared to 
NHW women. These results appear inconsistent with those of Katz, et al.,85 who 
observed that NHB and Hispanic women were more likely to receive a recommendation 
for mastectomy and received less information about BCS. However, they also observed 
racial differences in the surgical decision making process in which NHB and Hispanics 
were more likely to undergo mastectomy when they perceived the primary decision-
maker to be the surgeon compared to NHW women, who were much less likely to 
undergo mastectomy in that situation.85 Reasons for this unexpected propensity of 
NHWs compared to NHBs and Hispanics to choose more radical surgery, even though 
it does not improve overall survival, are unclear, but could involve fear of recurrence 
and better access to reconstructive surgery.63,65-67 Patient preferences among racial 
groups can also impact surgical decision making, including importance of having 
breasts and overall interest in breast preservation. In a recent study by Jagsi, et al.,88 
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NHB patients were less likely to undergo contralateral prophylactic mastectomy 
compared to NHWs, although uptake of this surgical procedure was low, particularly 
when a patient reported that their surgeon recommended against it. Unfortunately, with 
SEER data alone these discrepancies cannot be addressed. This is an area for future 
investigation to understand how patient involvement in shared decision-making 
regarding the treatment of their breast cancer can be maintained without leading to 
overtreatment. 
 
HER2 status and disparities in Luminal breast cancers 
 In this second study, associations were examined among Luminal breast cancers 
and socioeconomic status as assessed by age, race/ethnicity, and a census level 
measurement of county-level poverty and found that within Luminal A (HR+/HER2-) and 
Luminal B (HR+/HER2+) cancers, clinical and demographic characteristics varied. 
Consistent with the findings	 that clinical differences among luminal breast cancers can 
be attributed to the opposing effects of estrogen and progesterone on tumor 
progression,12-14 it was observed in this study that regardless of HER2 status, women 
with ER-/PR+ tumors were more likely to present with later stage (stage III-IV) disease 
compared to ER+/PR+ or ER+/PR- cases. These results suggest that differences in 
HR+ (ER-/PR+ versus ER+/PR- or ER+/PR+) tumor biology are likely to be clinically 
significant and play a role in breast cancer disease, regardless of HER2 status. 
Demographic characteristics of patients, including age, also varied within each 
Luminal breast cancer subtype. Progesterone levels are higher in pre-menopausal 
women, typically those diagnosed with breast cancer under the age of 50 years, 
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compared to post-menopausal women over the age of 60.52,53 This study showed that 
women under the age of 50 were at an increased risk of developing ER-/PR+ Luminal A 
disease, while women over the age of 60 were at a decreased risk compared to 
ER+/PR+ disease. This observation is consistent with reports that high progesterone 
levels (occurring only in the luteal phase and in pregnancy) will induce breast cancer 
cell invasiveness and metastasis in the absence of estrogen or the estrogen receptor. In 
contrast, age was not associated with increased risk of ER-/PR+ disease among 
Luminal B cases. This observation may be explained by findings using experimental 
models, that overexpression of HER2 supports aggressive tumor growth in luminal 
breast cancers.89 
  Racial and ethnic differences were also noted among Luminal A cancers, as non-
Hispanic black women were most likely to develop ER-/PR+ disease. Indeed, previous 
studies have demonstrated that among Luminal A tumors, race-associated biological 
factors contribute to poorer outcomes in black women compared to non-Hispanic white 
women.23,24 Among women with Luminal B tumors, non-Hispanic Asian or Pacific 
Islander or American Indian/Alaska Native individuals were at an increased risk of 
developing ER-/PR+ tumors. However, caution should be taken in interpreting results in 
these racial/ethnic categories due to small sample size. Earlier findings have observed 
that Hispanic white women are more likely to present with more aggressive tumors and 
be diagnosed with ER+/PR- disease.90 In this study, Hispanic individuals were at an 
increased risk of developing ER+/PR- or ER-/PR+ disease compared to ER+/PR+ 
status in both Luminal A and B breast cancer subtypes after adjusting for age, race, and 
area-based poverty. 
32 
	
 
 
While clinical and patient characteristics differed within each luminal breast 
cancer subtype, disparities in socioeconomic status were found to persist only among 
Luminal A tumors. Luminal A breast cancers are associated with the most favorable 
short-term prognosis due to favorable responses to endocrine therapy.11,12 However, 
assessment of long-term prognosis demonstrates similar or worse overall survival for 
Luminal A cases as compared to other subtypes.13 In this study, among Luminal A 
cases, it was observed that ER-/PR+ disease was associated with residing in areas of 
higher poverty even after adjusting for age and race/ethnicity. Caution should be 
exercised in the interpretation for results of ER-/PR+ cases due to small sample size. 
The relationship between socioeconomic status and development of Luminal A breast 
cancers demonstrates that while race and SES are correlated, each plays an 
independent role in contributing to disease among Luminal A tumors. These disparities 
were not observed among Luminal B tumors, suggesting that HER2 status may be 
associated with risk factors that affect the socioeconomic status of patients. 
This study is the first to assess disparities among hormone receptor-positive 
(HR+) breast cancer subtypes in the context of HER2 status using SEER patient data. 
Previous studies have investigated the role of HR+ status without HER2 information, or 
have analyzed the role by breast cancer subtype. For example, a recent study by 
Parise, et al. that used the California Cancer Registry found that socioeconomic status 
moderately altered racial disparities and risk of mortality in particular breast cancer 
subtypes.91 Similar results have been observed among other tumor sites.92 While these 
findings suggest differences within Luminal A or B breast cancer subtypes, available 
data for HER2 are limited to three years of diagnosis, which does not allow further 
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analysis for SES disparities in mortality at this time. The use of data from the 
population-based SEER program is a strength of this study, as it allows for the inclusion 
of a considerable number of pathologically verified cases making these results more 
generalizable to the larger United States population. Another strength is that these data 
are of high quality and database entries are standardized and continuously monitored 
for accuracy. However, use of SEER data does have limitations. Family history, 
lifestyle-related factors (eg. obesity, reproductive factors, and environmental 
exposures), modality of diagnosis, and chemotherapy data, are not available for study. 
Patients whose ER, PR, or HER2 status was unknown were also unable to be 
examined.  
Scientific, clinical, and public health implications can be inferred from this study. 
First, the findings are consistent with preclinical and clinical data regarding the opposing 
effects of the estrogen and progesterone receptors in breast cancer growth and 
progression. Further research is needed to analyze the opposing effects of hormone 
receptors in the context of HER2 status. Hormone receptor-positive (HR+) breast 
cancers are currently defined as ER and/or PR-positive tumors. In addition, these 
observations suggest that additional work is required to assess clinical differences 
observed, particularly between ER-/PR+ and ER+/PR- breast cancers, as this 
information could potentially be used to improve systemic adjuvant treatments. 
Disparities in socioeconomic status among Luminal A (HR+/HER2-) breast cancer 
patients may be associated with risks of recurrence and mortality, and identifying 
barriers in patient access to medical care can seek to improve patient outcomes in 
underserved, high-risk populations.  
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Conclusions 
Taken together, these findings conclude that: (1) for women age<40 years 
diagnosed with early-stage breast cancer, NHB and Hispanic women are considerably 
less likely to undergo mastectomy compared to NHWs, a disparity that was most 
striking for HER2-enriched tumors; (2) while race/ethnicity and socioeconomic status 
are correlated, each plays an independent role in contributing to disease among 
Luminal A tumors. 
Identification of age-related, racial, and ethnic disparities in uptake of surgical 
therapy for breast cancer contribute to improved understanding of the reasons for 
NHWs to choose more radical surgery, even though it does not improve overall survival. 
Further, detailed investigations of differences in tumor biology and association of 
race/ethnicity and socioeconomic status among hormone receptor-positive breast 
cancers, particularly those with HER2-negative status (HR+/HER2-), may lead to the 
identification of additional prognostic markers, direct resources to underserved 
populations for screening, and improve adjuvant treatments to better long-term patient 
outcomes. 
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PATIENTS AND METHODS 
 
Data Sources and Case Selection 
Data were obtained from the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) program.93 The SEER program collects cancer 
incidence and mortality data from 18 population-based cancer registries covering 
approximately 30 percent of the US population.7 SEER*Stat is a free program provided 
by SEER to access and analyze information in the publically available database. The 
SEER 18 incidence dataset includes information from the following registries: Alaska 
Native Tumor Registry, Arizona Indians, Cherokee Nation, Connecticut, Detroit, Atlanta, 
Greater Georgia, Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Greater 
California, Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, 
Seattle-Puget Sound, and Utah. The dataset used is publicly available and was exempt 
from human subjects review. Therefore, an Institutional Review Board (IRB) protocol 
was not required for these studies. 
 
Disparities in surgical therapy among female patients with young onset early-stage 
breast cancers analysis 
 The analysis was restricted to women diagnosed during the years 2010 to 2013 
in this study (n=244,819), as diagnosis year 2010 is the first year for which HER2 
(human epidermal growth factor receptor 2) status data are available. Study data, 
including breast cancer subtype, demographic characteristics, tumor stage, and surgical 
therapy were identified across SEER registries using standardized coding protocols 
based on pathology reports and hospital medical records. Case patients diagnosed with 
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adenocarcinomas, including ductal, lobular, and mixed neoplasm histology, were 
included (n=799 excluded). Patients aged ≥40 years at diagnosis were excluded 
(n=232,761), and analysis was limited to women diagnosed with American Joint 
Commission of Cancer (AJCC) clinical stage I-II tumors (n=3,309 excluded), with intent 
concentrate on patients whose primary therapy is most commonly surgery. Patients with 
self-reported race/ethnicity classified as non-Hispanic white (NHW), non-Hispanic 
African American or black (NHB), and Hispanic were included; subjects whose race was 
coded as Asian or Pacific Islander, American Indian or Alaskan Native, other, or 
unknown were not included in this analysis due to small sample size (n=1,137). Patients 
who did not undergo surgical therapy were also excluded (n=362). The final cohort thus 
consisted of 6,449 female patients with primary young-onset early-stage breast cancer. 
Clinical and demographic variables examined included: age at diagnosis (5-year 
groups), AJCC stage (IA-B, IIA-B), surgical therapy (BCS or mastectomy), tumor size 
(≤5.0 cm versus >5.0 cm), nodal involvement (yes/no), radiation therapy (yes/no), and 
insurance status (insured, uninsured, Medicaid). Breast cancer subtype was derived 
from SEER based on joint hormone receptor (HR) and HER2 status, and tumors were 
classified into four mutually-exclusive categories: HR+/HER2- (Luminal A), HR+/HER2+ 
(Luminal B), HR-/HER2+ (HER2-enriched), and HR-/HER2- (triple negative). Surgical 
therapy (BCS versus mastectomy) was categorized based on SEER program surgical 
summary codes. BCS was defined as removal of the gross primary tumor and some of 
the breast tissue and included SEER surgery codes 20-24: partial mastectomy, 
lumpectomy, re-excision of the biopsy site and segmental mastectomy. Mastectomy 
was defined as removal of all breast tissue with or without removal of the nipple-areolar 
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complex. Mastectomy procedures included SEER surgery codes 30, 40-76, 80: 
subcutaneous (nipple sparing) mastectomy; total (simple) mastectomy with or without 
removal of uninvolved contralateral breast; modified radical mastectomy; bilateral 
mastectomy; radical mastectomy; extended radical mastectomy; and mastectomy, 
NOS. 
Differences in demographic and tumor characteristics by race were examined by 
chi-square tests for categorical variables and t-tests for continuous variables. Logistic 
regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) to 
quantify associations between surgical therapy (mastectomy as the outcome with BCS 
as referent) and various demographic/clinical factors. Demographic variables assessed 
included: age (5 year groups), race/ethnicity (NHW, NHB, Hispanic), and insurance 
status (insured, uninsured, Medicaid). Clinical variables assessed included: breast 
cancer subtype and AJCC stage. Models were adjusted for age, race/ethnicity, stage, 
tumor size, nodal involvement, radiation therapy, and insurance status; based on 
patients having complete information for each of these covariables. Analyses were then 
stratified by subtype. 
 
HER2 and socioeconomic disparities in luminal breast cancers analysis 
A case listing session in SEER*Stat was run on the SEER 18 incidence dataset 
to obtain demographic, tumor characteristics, and socioeconomic information on breast 
cancers. Women with invasive breast cancer diagnosed from 2010 to 2012 were 
included in this study. Diagnosis year 2010 is the first year for which HER2 status data 
were available. Study data, including ER, PR, and HER2 status, demographic 
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characteristics, and tumor stage, were identified across SEER registries using 
standardized coding rules based on pathology reports and hospital medical records. 
Case patients diagnosed with nevi and melanomas; soft tissue tumors and sarcomas, 
NOS; fibromatous neoplasms; lipomatous neoplasms; myomatous neoplasms; 
fibroepithelial neoplasms; synovial-like neoplasms; blood vessel tumors; osseous and 
chondromatous neoplasms; miscellaneous bone tumors; gliomas; nerve sheath tumors; 
and granular cell tumors & alveolar soft part sarcoma histologies were excluded. To 
assess breast cancer subtype, tumors were classified into six mutually exclusive 
categories: ER+/PR+/HER2-; ER+/PR-/HER2-; ER-/PR+/HER2-; ER+/PR+/HER2+; 
ER+/PR-/HER2+; ER-/PR+/HER2+. Analysis was restricted to exclude patients without 
positive/negative ER, PR, or HER2 statuses (n=19,020). Case patients with ER-/PR-
/HER2+ (HER2-enriched), and ER-/PR-/HER2- (basal-like) receptor status were also 
excluded (n=26,736). The final analytic data set consisted of 134,639 breast cancer 
patients. 
The variables of interest included age at diagnosis (<50, 50-64, 65-74, 75+ 
years), race/ethnicity (non-Hispanic (NH) white, non-Hispanic black, non-Hispanic Asian 
or Pacific Islander, non-Hispanic American Indian, Hispanic), American Joint 
Commission of Cancer (AJCC) clinical stage, and tumor size (≤0.5 cm, >0.5 cm). An 
approximation of socioeconomic status (SES) was evaluated using contextual 
measures of area-based poverty. The percent of persons and families whose incomes 
were below 200% of the poverty level were calculated in SEER using county attribute 
data from the US Census Bureau’s 2008-2012 American Community Survey. The 
cohort of breast cancer cases was categorized into quartiles based on the percentage 
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of persons with incomes below 200% of the poverty level distribution within the data set. 
Quartile 1 (Q1) (<24%) represented the fourth of the cohort that reside in areas where 
less than 24% of residents are low income. Quartile 2 (Q2) (24%≤31% low income), 
quartile 3 (Q3) (31%≤39%), and quartile 4 (Q4) (>39%) were defined such that Q4 
contained the fourth of the cohort that reside in areas with the highest proportion of low 
income residents. Follow-up for each case was current within 22 months of the annual 
submission date (November 1, 2014). 
Pair-wise comparisons of hormone receptor categories by demographic and 
tumor characteristics were examined using chi-square tests. Multinomial logistic 
regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) to 
quantify associations between breast cancer hormone receptor status and various 
demographic factors. Analyses were stratified by HER2 status and the reference 
outcome category was ER+/PR+ disease. Demographics variables assessed, included: 
age at diagnosis (<50, 50-64, 65-74, 75+), race/ethnicity (NH white, NH black, NH Asian 
or Pacific Islander, NH American Indian, Hispanic), and area-based poverty level 
(quartiles).  These factors were adjusted for age, race/ethnicity and poverty level, based 
on patients having complete information for each of these co-variables.  
 
Statistical analysis 
All data were analyzed using SAS version 9.4 statistical software (SAS Institute; 
Cary, NC). All statistical tests were two-sided. A p-value of <0.05 was considered to be 
statistically significant.  
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CHAPTER 3. CLINICOPATHOLOGY AND MOLECULAR PRECURSORS 
FOR TIME TO BREAST CANCER AMONG WOMEN WITH BENIGN 
BREAST LESIONS 
 
INTRODUCTION 
 
Each year in the United States, over 1.5 million breast biopsies are 
performed.94,95 The majority of these lesions are classified as benign;96 however, benign 
breast disease (BBD) is an established breast cancer risk factor, among which distinct 
pathological features are associated with higher risk of malignancy.2,97-100 Benign breast 
disease pathological features are loosely categorized into three groups using Dupont 
and Page criteria, where proliferative disease with atypia, or atypical hyperplasia, is 
associated with the greatest risk of subsequent breast cancer diagnosis and 
nonproliferative disease without atypia is associated with lowest risk.101-103  
Other pathological findings, including columnar alterations (Figure 12D), can also 
contribute to an increased risk of subsequent breast cancer development (Figure 
13).104-106 Columnar cell lesions of the breast represent the morphological spectrum of 
alterations that includes: columnar cell change and columnar cell hyperplasia.107 
Increasing studies have shown that columnar alterations may be a marker of breast 
cancer risk in women with benign breast disease.104 Yet the clinical relevance of these 
alterations is still undetermined.105 Additional benign breast disease pathological 
features such as cysts, ductal ectasia, ductal hyperplasia, intra-ductal papilloma, lobular 
hyperplasia, and schlerosing adenosis also trended towards an increased relative risk of 
subsequent breast cancer development in black women (Figures 12 & 13).
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Figure 12. Microscopic view of (A) 
apocrine metaplasia, (B) 
atrophy/involution, (C) calcifications, 
(D) columnar alterations, (E) cyst, (F) 
ductal ectasia, (G) ductal 
hyperplasia, (H) fibroadenoma, (J) 
fibrosis, (K) lobular hyperplasia, and 
(L) schlerosing adenosis features in  
benign breast biopsy tissues from 
black women in the Detroit BBD 
cohort. Magnification: 100X.  
Photographs courtesy of E. Abdulfatah, Wayne State University, Department of Pathology. 
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In contrast, lobular involution or atrophy has also been associated with breast 
cancer risk, with higher proportions of involution being protective (Figures 12B & 13). 
Previous studies have shown that  higher proportions of atrophy are indeed associated 
with a decreased risk of breast cancer development, although given the small sample 
size of patients this association was not found to be significant (Figure 13). Thus, there 
is a critical need to understand risk factors unique to the black population to identify 
high-risk women who can benefit from closer surveillance, earlier diagnosis and better 
patient prognosis.2 
Although it has been shown that benign breast lesions confer an increased 
breast cancer risk among both blacks and whites,2,99,100,103 little is known about the 
molecular profiles of benign breast lesions and subsequent breast tumorigenesis, 
particularly in the black population. Gene expression profiling on breast biopsy tissue 
from black and white women was recently performed by Field et al. and demonstrated 
differences in molecular profiles between races, but these nonmalignant tissues 
demonstrated no evidence of benign conditions.108 No studies to date have examined 
the transcriptome of benign breast lesions from black women. Thus, this study sought to 
identify novel molecular precursors that can predict shorter time to breast cancer 
diagnosis among benign breast lesions of black women. Profiling the transcriptome of 
these premalignant lesions served to help identify black women diagnosed with benign 
breast disease at highest risk who could largely benefit from increased surveillance, 
chemopreventive strategies, and earlier detection, leading to improved survival.  
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Figure 13. Pathological characteristics of benign breast tissue from biopsies and association with risk of 
subsequent breast cancer among black women in metropolitan Detroit. Adapted from Cote, et al.2 Copyright 
permissions for re-use of this figure were obtained from the American Association for Cancer Research (AACR). 
 
  Breast Cancer Status Relative Riska p value 
  Negative Positive  (95% C.I.) 
Apocrine Metaplasia 
    No 927 38 1.0 (Ref) 
 Yes 422 17 0.93 (0.52-1.67) 0.80 
Atrophy/Involution 
    None 237 11 1.0 (Ref) 
 Partial 700 27 0.75 (0.37-1.55) 0.44 
Complete 218 12 0.84 (0.34-2.07) 0.71 
Columnar Alterations 
    No 1127 40 1.0 (Ref) 
 Yes 222 15 1.84 (0.99-3.39) 0.05 
Cyst 
    No 809 28 1.0 (Ref) 
 Yes 540 27 1.41 (0.82-2.42) 0.21 
Ductal Ectasia 
    No 1294 52 1.0 (Ref) 
 Yes 57 3 1.33 (0.40-4.41) 0.64 
Ductal Hyperplasia 
    None 928 36 1.0 (Ref) 
 Yes  415 19 1.14 (0.64-2.01) 0.66 
Fibrosis 
    No 505 21 1.0 (Ref) 
 Yes 749 31 0.97 (0.55-1.71) 0.91 
Intra-Ductal Papilloma 
    None 1220 48 1.0 (Ref) 
 1 or more 130 7 1.26 (0.55-2.84) 0.59 
Lobular Hyperplasia 
    No 1330 54 1.0 (Ref) 
 Yes 21 1 1.08 (0.14-8.21) 0.94 
Sclerosing Adenosis 
    No 1266 48 1.0 (Ref) 
 Yes 84 7 2.20 (0.96-5.01) 0.06 
Overall Impression 
    Non-Proliferative Disease 912 33 1.0 (Ref) 
 Proliferative Disease without Atypia 388 17 1.16 (0.64-2.12) 0.62 
Proliferative Disease with Atypia 39 5 3.29 (1.21-8.93) 0.02 
aAdjusted for age and year at biopsy.  
CI: confidence interval 
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RESULTS: 
 
CLINICOPATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF 
BENIGN BREAST LESIONS FROM BLACK WOMEN SUBSEQUENTLY 
DIAGNOSED WITH BREAST CANCER 
 
 
Clinicopathological characteristics of study cohort 
 
A total of 3,759 black women from metropolitan Detroit with benign breast lesions 
comprise the Detroit benign breast disease cohort. Among these individuals, thirty-six 
women who were subsequently diagnosed with breast cancer were selected based on 
tissue availability (16.6%, 36 of 217 cases) to comprise this study sample (Figure 14). 
Mean age at first breast biopsy among these women was 55.3 years, ranging from 29 to 
76 years. Similar to the entire benign breast disease cohort,2 half of the benign samples 
were from excisional biopsies (n=18, 50%) and half were from core needle biopsies 
performed between 1997 and 2003.  
Evaluation of other breast cancer risk factors, such as patient body mass index 
(BMI), revealed that the 72.2% of women (26 of 36 cases) were classified as overweight  
(BMI: 25- ≤30 kg/m2) or obese (BMI: >30 kg/m2) (Figure 14). BMI ranged from 20.5 to 
52.9 kg/m2, with a mean BMI in this cohort of 30.7 (sd 8.8). A self-reported history of 
breast cancer in first-degree relatives was observed in 36.1% of cases, whereas over 
61.1% (22 of 36 cases) reported a familial history of cancer. Further, 13.9% of cases (5 
of 36) underwent menarche at an early age, between 9 to 11 years, and 13.9% of 
women were nulliparous in this cohort. In total, 63.9% of women were clinically 
assessed as post-menopausal (Figure 14). A known history of cigarette smoking was 
reported for 47.2% of cases in this cohort (17 of 36 cases). 
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Figure 14. Clinical and demographic characteristics of thirty-six black women 
with benign breast lesions and a subsequent breast cancer diagnosis from 
the metropolitan Detroit cohort. 
 
 
 
  
Characteristic N % 
 
36 
 Age at Breast Biopsy, years     
<50 11 30.6% 
50-59 12 33.3% 
60-64 8 22.2% 
70+ 5 13.9% 
Mean (sd, years) 55.2 (11.4) 
Year of Breast Biopsy 
  1997-1999 14 38.9% 
2000-2001 12 33.3% 
2001-2003 10 27.8% 
Type of Breast Biopsy     
Excisional 18 50.0% 
Core/Needle 18 50.0% 
Body Mass Index (kg/m2)     
Normal (18.5 - ≤25)   10 27.8% 
Overweight (25- ≤30)  12 33.3% 
Obese, Class I (30- ≤35) 5 13.9% 
Obese, Class II (35+)  9 25.0% 
Mean (sd, kg/m2) 30.7 (8.8) 
Breast Cancer History in First-Degree Relatives 
No 18 50.0% 
Yes 13 36.1% 
Unknown 5 13.9% 
Age at Menarche, years 
  9-11  5 13.9% 
12-13 13 36.1% 
14+ 9 25.0% 
Unknown 9 25.0% 
Menopausal Status     
Pre-menopausal  2 5.6% 
Peri-menopausal  4 11.1% 
Post-menopausal  23 63.9% 
Unknown 7 19.4% 
Number of Pregnancies 
  0 5 13.9% 
1-2 8 22.2% 
3-4 10 27.8% 
5+ 6 16.7% 
Unknown 7 19.4% 
Cigarette Smoking History 
  No 17 47.2% 
Yes 17 47.2% 
Unknown 2 5.6% 
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Figure 15. Pathological features and overall impression of benign breast lesions from thirty-six black women who were 
subsequently diagnosed with breast cancer from the metropolitan Detroit cohort. TDLU, terminal duct lobular unit. 
 
  
Feature N % 		 Feature N % 	 36 	 	 	 36 	
Apocrine Metaplasia˚   	 Fibrosis˚   
No 22 62.90% 	 No 16 45.70% 
Yes 13 37.10% 	 Yes 18 51.40% 
Atrophy/Involution 	 	 	 Marked 1 2.90% 
No 11 30.60% 	 Intraductal Papilloma˚ 	 	
1-24% TDLU 14 38.90% 	 No 30 85.70% 
25-74% TDLU 9 25.00% 	 Single 4 11.40% 
Unknown 2 5.60% 	 Multiple 1 2.90% 
Calcifications˚   	 Mucocele-Like Lesions˚   
No 16 45.70% 	 No 35 100.00% 
Yes 19 54.30% 	 Yes 0 0.00% 
Columnar Alterations˚ 	 	 	 Lobular Hyperplasia˚ 	 	
No 20 57.10% 	 No 35 100.00% 
Yes 14 40.00% 	 Yes 0 0.00% 
Atypia 1 2.90% 	 Radial Scar   
Cyst˚   	 No 32 88.90% 
No 13 37.10% 	 Yes (<5 mm) 4 11.10% 
Yes 22 62.90% 	 Sclerosing Adenosis˚ 	 	
Ductal Ectasia˚ 	 	 	 No 29 82.90% 
No 31 88.60% 	 Yes 6 17.10% 
Atypical 4 11.40% 	 Overall Impression   
Ductal Hyperplasia˚   	
Non-proliferative disease without 
atypia 17 47.20% 
No 20 57.10% 	
Proliferative disease without 
atypia 15 41.70% 
Atypical 3 8.60% 	 Atypical hyperplasia 4 11.10% 
Mild 6 17.10% 	 Breast Cancer Behavior   
Moderate/Florid 6 17.10% 	 Ductal carcinoma in situ 10 27.80% 
Fibroadenoma 	 	 	 Invasive ductal carcinoma 26 72.20% 
No 25 69.40% 	 ˚Pathology review for 1 case noted that this benign breast feature was not 
applicable in the lesion. Yes 11 30.60% 		
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Figure 15 presents the pathological features of benign breast biopsies. The 
majority of the sample presented with cysts (62.9%), calcifications (54.3%), and fibrosis 
(51.4%). Proliferative disease with atypia, atypical hyperplasia, was present in 11.1% of 
cases. Of these patients, 27.8% of patients (10 of 36 women) went on to develop ductal 
carcinoma in situ (DCIS), while 62.2% (26 of 36 women) were diagnosed with invasive 
ductal carcinoma (Figures 2 & 15). At fifteen years, the cumulative incidence for breast 
cancer was 2.24% for DCIS and 5.34 % for invasive ductal carcinoma, with a median 
time of 6.4 years to breast cancer diagnosis (Figure 16). Mean age at subsequent 
breast cancer diagnosis was 62.1 years (sd 11.4 years; data not shown). 
Figure 17 highlights clinical and demographic characteristics of subsequent 
breast cancer cases diagnosed between 1999 and 2012 among the thirty-six women in 
the study sample. Mean age at diagnosis among the 10 cases of DCIS was 58.3 years 
(sd 10.4 years), while mean age at diagnosis for invasive breast cancer cases was 
older, with 63.5 years (sd 11.7 years). ER status was positive among all DCIS cases 
with known receptor information, while 69.2% of all invasive breast cancer cases were 
classified as ER-positive (Figure 17). Further assessment of progesterone receptor 
status revealed that 80.0% of all DCIS cases were positive, in comparison to 73.1% of 
invasive cancer cases. Evaluation of HER2 status revealed that no cases of DCIS were 
positive among those that could be evaluated, and 11.5% of all invasive cases were 
HER2-positive. Notably, 23.1% of invasive breast cancers (6 of 26 cases) were found to 
be of the triple negative subtype (ER-/PR-/HER2-negative) (data not shown).  
Examination of primary tumor size revealed that 15.4% of all invasive breast 
cancers were larger than 5 centimeters in size, indicating these cases would be 
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Figure 16. Cumulative incidence for in situ and invasive breast cancer among 217 
black women with benign breast lesions in the Detroit BBD cohort. (63 in-situ cancers 
and 154 invasive cancers). Figure generated using R software. 
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Figure 17. Demographic and pathological characteristics of breast cancers from thirty-six 
black women with benign breast disease in metropolitan Detroit.  
 
 
   
  In situ   Invasive 
Characteristic N % 
 
N % 
 
10 
  
26 
 Age at Diagnosis, years           
<50 1 10.0%   2 7.7% 
50-59 6 60.0%   8 30.8% 
60-69 1 10.0%   7 26.9% 
70+ 2 20.0%   9 34.6% 
Mean (sd, years) 58.3 (10.4)   63.5 (11.7) 
Year of Diagnosis 
     1999-2003 3 30.0% 
 
5 19.2% 
2004-2008 6 60.0% 
 
11 42.3% 
2009-2012 1 10.0% 
 
10 38.5% 
Estrogen Receptor (ER) Status           
Negative 0 0.0%   8 30.8% 
Positive 9 90.0%   18 69.2% 
Unknown 1 10.0%   0 0.0% 
Progesterone Receptor (PR) Status 
     Negative 1 10.0% 
 
7 26.9% 
Positive 8 80.0% 
 
19 73.1% 
Unknown 1 10.0% 
 
0 0.0% 
HER2 Status           
Negative 9 90.0%   23 88.5% 
Positive 0 0.0%   3 11.5% 
Unknown 1 10.0%   0 0.0% 
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diagnosed with AJCC stage IIB or higher clinical stage (Figure 18). Over half of all 
invasive cases demonstrated regional lymph node involvement (53.8%), as compared 
to 30.0% of DCIS cases. While 20.0% of women diagnosed with DCIS received 
chemotherapy, 61.5% of the individuals diagnosed with invasive breast cancer received 
chemotherapy in a neoadjuvant or adjuvant setting (16 of 26 cases) (Figure 18). For 
both DCIS and invasive cancers, the majority of these black women underwent breast-
conserving surgery (60.0% and 57.7% of DCIS and invasive cases, respectively). 
76.9% of invasive cases underwent radiation in first course of treatment, while in 
contrast the majority of women diagnosed with DCIS did not receive radiation therapy. 
At last follow-up, 77.8% of all black women in the study cohort were alive (Figure 18). 
 
Molecular precursors for time to cancer among black women with benign breast lesions 
To investigate molecular precursors of benign breast lesions associated with 
shorter time to breast cancer diagnosis, LHRs for 67,528 transcripts were calculated, 
adjusted for age at breast biopsy and overall impression of the benign breast lesion. 
18,749 transcripts (absolute LHR>1.0 and p-value<0.05) were entered into Ingenuity 
Pathway Analysis (IPA) software (Figure 19). The top up-regulated molecule associated 
with time to breast cancer diagnosis was histone lysine demethylase 4C (KDM4C) 
(LHR, 12.949; p-value=0.00177), and the top down-regulated molecule was deformed 
epidermal autoregulatory factor 1 (DEAF1) (LHR, -9.865; p-value=0.00227) (Figure 20).  
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Figure 18. Clinical characteristics of breast cancer from thirty-six black women with benign 
breast disease in metropolitan Detroit.  
 
 
 
   
  In situ   Invasive 
Characteristic N % 
 
N % 
 
10 
  
26 
 Tumor Size 
     Microscopic foci 2 20.0% 
 
0 0.0% 
≤ 5 cm 5 50.0% 
 
22 84.6% 
> 5 cm 1 10.0% 
 
4 15.4% 
Unknown 2 20.0% 
 
0 0.0% 
Regional Lymph Nodes 
 
    
 
  
Not examined 7 70.0%   2 7.7% 
Negative 3 30.0%   14 53.8% 
Positive 0 0.0%   10 38.5% 
Chemotherapy 
     No 8 80.0% 
 
7 26.9% 
Yes 2 20.0% 
 
16 61.5% 
Unknown 0 0.0% 
 
3 11.5% 
Surgery 
 
    
 
  
None 0 0.0%  2 7.7% 
Breast-conserving surgery 6 60.0%   15 57.7% 
Mastectomy 4 40.0%   9 34.6% 
Radiation Therapy 
     No 8 80.0% 
 
6 23.1% 
Yes 2 20.0% 
 
20 76.9% 
Vital Status 
 
    
 
  
Alive 9 90.0%   19 73.1% 
Deceased 1 10.0%   7 26.9% 
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Figure 19. Analysis flowchart for the study. 
 
 
 
  
Affymetrix human transcriptome array 
2.0 (HTA 2.0) exon array chip 
	
N = 67,528 transcripts	
Cox proportional hazards modeling	
Exclude: p-value ≥ 0.05	
Remaining transcripts 	
N = 20,741	
Exclude: Transcripts with LHR ≤ 1.0 	
(absolute value)	
Total genes	
N = 1,802	
Remaining transcripts	
N = 18,749	 Exclude: Transcripts that were not mapped 
to genes by Ingenuity Pathway Analysis 
(IPA) software	
Remaining genes	
N = 9,411	
Exclude: Transcripts that were duplicates by 
IPA (IPA consolidated transcript IDs using 
absolute maximum value)	
Remaining genes	
N = 8,075	
Exclude: Genes with p-value > 0.01	
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Figure 20. Gene expression profiling data of top up- and down-regulated molecules associated with shorter time to 
breast cancer among benign breast biopsy lesions from thirty-six black women. 
  
Log 
Hazard 
Ratio 
p-value Transcript Cluster ID Symbol Entrez Gene Name 
12.949 0.00177 TC09002929.hg.1 KDM4C lysine demethylase 4C 
11.682 0.00008 TC11002221.hg.1 TRPC6 transient receptor potential cation channel subfamily C member 6 
10.3 0.00393 TC21000441.hg.1 DSCR3 DSCR3 arrestin fold containing 
9.523 0.00003 TC0X000084.hg.1 NHS NHS actin remodeling regulator 
8.923 0.00178 TC07001050.hg.1 NOM1 nucleolar protein with MIF4G domain 1 
-8.072 0.00068 TC02000440.hg.1 CCT7 chaperonin containing TCP1 subunit 7 
-8.227 0.00406 TC13000217.hg.1 WDFY2 WD repeat and FYVE domain containing 2 
-8.39 0.00214 TC05001005.hg.1 TSPAN17 tetraspanin 17 
-9.308 0.00235 TC19001497.hg.1 YIF1B Yip1 interacting factor homolog B, membrane trafficking protein 
-9.865 0.00227 TC11001244.hg.1 DEAF1 DEAF1, transcription factor 
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RESULTS: 
 
HISTONE LYSINE DEMETHYLASE 4C, KDM4C: THE TOP UP-REGULATED 
MOLECULE ASSOCIATED WITH TIME TO BREAST CANCER DIAGNOSIS 
 
 Of the 67,528 transcripts that were evaluated through gene expression profiling, 
analyses revealed that KDM4C was the top up-regulated molecule to be associated with 
a shorter time to breast cancer diagnosis among black women with benign breast 
disease (Figure 20). Strikingly, my early doctoral work under the mentorship of Zeng-
Quan Yang, was primarily focused on the dysregulation of histone lysine demethylases 
in cancers, and in particular the expression patterns and molecular mechanism of 
KDM4C in breast cancer. 
Histone demethylases play essential roles in dynamically regulating gene 
expression and chromatin architecture through histone lysine methylation, and are thus 
implicated in developmental processes and tumorigenesis.109-112 Many lines of evidence 
suggest that genetic alteration and dysregulation of histone lysine demethylases are 
associated with breast cancer initiation and progression, where the effect is to activate 
expression of oncogenes, repress expression of tumor suppressors, alter DNA 
mismatch repair, disrupt chromosomal stability, or interact with key hormonal receptors 
which control cellular proliferation.3,113-115 
Histones can be post-translationally modified through covalent addition of a 
number of distinct chemical moieties through dynamic processes, including 
methylation.116-120 Methylation at various lysine residues, degree of methylation, and 
location of the methylated histone within a specific gene locus all yield different 
transcriptional and biological outcomes. Histone lysine methylation is the principal 
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chromatin-regulatory mechanism that influences fundamental nuclear processes and 
gene expression. Histone methylation is known to occur on the lysine residues of 
histones 3 and 4 (H3, H4), and the linker histone H1, isotype 4 (H1.4), and modifications 
of these residues are associated with distinct functional outcomes. Methylation of H3K4, 
H3K36 and H3K79 is generally associated with gene activation, while methylation of 
H3K9, H3K27, H3K56, H4K20 and H1.4K26 is linked to transcriptional repression.121,122 
Structurally, the histone lysine demethylases are a diverse group of proteins that 
can be subdivided into two distinct groups based on their mechanism of demethylation. 
Amine oxidase demethylases, the first group, can oxidize their substrate by FAD to 
generate an imine that gets hydrolyzed (Figure 21A).5,123 Histone lysine demethylases 
regulate chromatin architecture and transcription, and play critical roles in epigenetic 
signaling. The first functional enzymatic family of histone lysine demethylases in 
humans includes the lysine specific demethylase (LSD1, also known as KDM1A), 
which, along with the structurally similar KDM1B (LSD2), consist of the flavin adenine 
dinucleotide (FAD)-dependent amine oxidases, which can remove mono- and dimethyl 
histone lysine marks.124-126 These amine oxidases, however, are unable to demethylate 
tri-methyl lysine residues since they require a lone pair of electrons only present on 
mono- and dimethyl lysine histone residues.  
The other known 32 histone lysine demethylases belong to the JmjC (JumonjiC)-
domain containing group.3,127 These demethylases are characterized by a JmjC domain 
with defined enzymatic activity. Residues within predicted cofactor binding sites are 
conserved.123 The mechanism of demethylation requires five residues within the JmjC 
domain that bind to both the α-ketoglutarate (α-KG) and iron cofactors to undergo a 
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  Figure 21. Mechanisms of histone lysine demethylation.
5 (A) Mechanism of LSD1 demethylation via 
an amine oxidation reaction. (B) Mechanism of JmjC protein demethylation via a hydroxylation reaction.  
Figure designed using ChemDraw software. Open access copyright permissions for this article permitted 
re-use of this figure from Fly.	
 
Figure 2.
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hydroxylation reaction, which allow for removal of a methyl mark (Figure 21B).5 Often, 
the JmjC domain can be found in combination with other protein domains, which 
function in substrate specificity. Given the correlation between particular methyl marks 
and the transcriptional state of genes, it has been proposed that the activity of specific 
histone lysine demethylases contributes to different transcriptional and biological 
outcomes, depending on the histone lysine demethylase substrate.128-130 
 
 Genomic and protein structures of the KDM4 demethylase subfamily 
KDM4C, also referred to as JMJD2C or GASC1 (Gene Amplified in Squamous 
Cell Carcinoma 1), is overexpressed in numerous cancers including esophageal 
squamous cell carcinoma, breast and prostate cancers, medulloblastoma, metastatic 
lung sarcomatoid carcinoma, in primary mediastinal B-cell lymphoma and Hodgkin’s 
lymphoma, and in acute myeloid leukemia.131-138 Recurring evidence supports that 
KDM4C overexpression results from aberrant amplification of chromosome 9 at the 
9p23-24 foci.131 It is also aberrantly expressed as a fusion partner to the 
immunoglobulin heavy chain gene (IGH) in mucosa-associated lymphoma, following 9p 
translocation.139 
Previous studies have demonstrated that KDM4 genes are amplified and 
overexpressed in various tumor types, including lung, breast, esophageal, prostate 
cancers and lymphoma.131,134,138-140 KDM4C is part of the large KDM4 subfamily that 
consists of five functional KDM4 member genes (KDM4A-E) in humans (Figure 22). 
Genes encoding KDM4A, B and C localize to human chromosomes 1p34.1, 19p13.3, 
and 9p24.1, respectively. KDM4D localizes to human chromosome 11q21, and forms a 
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cluster with two additional intronless KDM4 genes, KDM4E and KDM4F.141 Previously, 
KDM4E and F were considered pseudogenes, however KDM4E expression has 
recently been observed, suggesting its role as a functional gene.121,142,143  
The KDM4A, B and C proteins, which share more than 50% sequence identity, 
each contain JmjN, JmjC, two plant homeodomains (PHD) and two Tudor domains. 
KDM4D and KDM4E, in contrast, are considerably shorter proteins that lack the C-
terminal region, including the PHD and Tudor domains (Figure 22). As with all JmjC-
domain containing demethylases, the KDM4 JmjC domain bears catalytic function while 
the JmjN domain interacts extensively with JmjC and provides structural integrity.133,144 
Beyond the catalytic core of KDM4A-C, the C-terminal PHD and Tudor domains bear 
important histone reader functions, likely contributing to efficient nuclear localization. 
Recent studies found that the Tudor domains of KDM4C are responsible for binding 
H3K4me3 activation marks at gene promoters.145 In addition, the PHD domains in other 
histone regulatory proteins have been demonstrated to bind unmodified, methylated, 
and/or acetylated histone residues on one or more histone tails, offering flexibility in 
directing epigenetic modifications. 
Previous studies have indicated that KDM4A and C are broadly expressed in 
mouse and/or human tissues, while KDM4D and E are predominantly expressed in the 
mouse testes.121,138,146,147 To establish a comprehensive profile of genomic alterations 
for KDM4A-E in human cancer, a large-scale meta-analysis was conducted of the 
genetic amplifications, deletions and mutations reported across 52 databases in the 
Cancer Genomics cBioPortal.148,149 An overview of these data reveal that KDM4A-E are 
altered across many tumor types (Figure 23). These data are complemented by a 
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Figure 22. Schematic structure and functional domains of the human KDM4 family: the N-terminal Jumonji (Jmj) 
domains form the histone demethylase catalytic core, whereas the C-terminal plant homeo domain (PHD) and Tudor 
domains mediate specific lysine recognition. 
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recent analysis of 4,934 cancer copy number profiles from The Cancer Genome Atlas 
(TCGA) Pan-Cancer data set, which has revealed significant amplifications of the 
KDM4C genomic region in human cancer cells.150 
 
Genetic alterations of KDM4 histone demethylases across breast cancer subtypes  
To systematically investigate genetic alterations of the KDM4 demethylases in 
breast cancer, genome sequencing data of 976 primary breast cancer samples were 
first analyzed from The Cancer Genome Atlas (TCGA) database via cBioPortal.148,149 In 
cBioPortal, copy numbers are computed using the GISTIC algorithm, which identifies 
the putative copy number level as high-level amplification, low-level gain, diploid, 
heterozygous deletion, or homozygous deletion.148,149 For mRNA expression analysis, 
the Z-score is used to determine whether a gene is upregulated or downregulated 
relative to normal adjacent tissue or relative to all other tumor samples that are diploid 
for the gene. KDM4C was found to have the highest frequency (13.4%) of genetic 
alteration, including high-level amplification, homozygous deletion, mutation, 
upregulation, and downregulation, whereas KDM4B had the lowest frequency (6.1%) of 
genetic alteration among the 976 TCGA breast cancer specimens (data not shown). For 
KDM4C, 2.5% of samples had high-level amplification and 0.7% had homozygous 
deletion, whereas 1.9% of samples had high-level amplification or homozygous deletion 
of KDM4A, B and D (Figure 24).1  
Correlations between gene expression and copy number have been used widely 
to prioritize driver oncogenes in human cancer, because mRNA expression can 
successfully translate the effect of elevated copy number to cancer initiation and 
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pression of tumor su- 
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ptors which control 
cellular proliferation 
[61-63]. Previous stu- 
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ated that KDM4 gen- 
es are amplified and 
overexpressed in var-
ious tumor types, inc- 
luding lung, breast, 
esophageal, prostate 
cancers and lympho-
ma [28, 57, 64-66]. 
To establish a com-
prehensive profile of 
genomic alterations 
for KDM4A-E in hu- 
man cancer, we con-
ducted a large-scale 
meta-analysis of the 
genetic amplificatio- 
ns, deletions and mu- 
tations reported acr- 
oss 52 databases in 
the Cancer Genomics 
cBioPortal [67, 68]. 
An overview of this 
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M4A-E are altered ac- 
ross many tumor ty- 
pes (Figure 2). This 
data is complement-
ed by a recent analy-
sis of 4,934 cancer 
copy number profiles 
from The Cancer Gen- 
ome Atlas (TCGA) Pa- 
n-Cancer data set, 
which has revealed 
significant amplifica-
tions of the KDM4C 
genomic region in 
human cancer cells 
[69]. The involveme- 
Figure 2. Alteration frequencies of KDM4 subfamily genes identified in human tumors 
of multiple origins reported across 52 databases held in the Cancer Genomics cBio-
Portal [67, 68]. Alteration frequencies are displayed for each of four categories, in-
cluding: genetic amplifications (red), deletions (blue), mutations (green) or multiple 
alterations (grey). 
Figure 23. Alteration frequencies of KDM4 subfamily genes identified in 
human tumors of multiple origins reported across 52 databases held in 
the Cancer Genomics cBioPortal.3 Alteration frequencies are displayed for 
each of four categories, including: genetic amplifications (red), deletions 
(blue), mutations (green) or multiple alterations (grey). Open access copyright 
permissions for this article permitted re-use of this figure from the American 
Journal of Translational Research.	
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the gene. As shown in Figure S1, we found that 
KDM4C had the highest frequency (13.4%) of 
genetic alteration, including high-level amplifi-
cation, homozygous deletion, mutation, upreg-
ulation, and downregulation, whereas KDM4B 
had the lowest frequency (6.1%) of genetic 
alteration among the 976 TCGA breast cancer 
specimens. For KDM4C, 2.5% of samples had 
high-level amplification and 0.7% had homozy-
gous deletion, whereas 1.9% of samples had 
high-level amplification or homozygous deletion 
of KDM4A, B and D (Figure 1A). 
Correlations between gene expression and 
copy number have been used widely to priori-
tize driver oncogenes in human cancer, because 
mRNA expression can successfully translate 
the effect of elevated copy number to cancer 
initiation and progression. Thus, we examined 
the association between copy number and 
mRNA expression of KDM4A, B, C and D by 
using Spearman’s rank correlation in TCGA 
breast cancer specimens. We found that the 
correlation between copy number and mRNA 
expression was strongest for KDM4C (R=0.61), 
followed by KDM4A (R=0.52); remaining KDM4 
members had correlation coefficients less than 
0.50 (R=0.44 for KDM4D, and R=0.28 for 
KDM4B) (Figure S2). 
Next, we determined whether the high-level 
amplification or expression level of each KDM4 
member was related to breast cancer subtype. 
Of the TCGA breast cancer samples, 493 had 
subtype data available, including 8 normal-like, 
220 Luminal A, 121 Luminal B, 55 HER2+, and 
89 basal-like breast cancers. Due to the small 
sample size (n=8) of the normal-like subtype, 
those samples were excluded from this analy-
sis. KDM4C and KDM4D amplification was 
found to have the highest frequency (12.4% 
and 3.6%, respectively) in basal-like breast 
cancer. The highest frequency of KDM4A ampli-
fication (3.6%) was in HER2-subtype samples, 
whereas KDM4B amplification (3.3%) was high-
est in Luminal B breast cancer. To determine 
Figure 1. KDM4A-D copy number and expression levels in different sub-
types breast cancer. A. High-level amplification and homozygous deletion 
of KDM4 subfamily members in TCGA breast cancer dataset (n=976). 
Data are displayed with the Oncoprint tool from cBioPortal. B. Frequen-
cies of high-level amplification of KDM4A, B, C, and D in different subtypes 
of breast cancer. C. Expression levels of KDM4A, B, C, and D across five 
subtypes of breast cancer based on TCGA database. The differences in 
KDM4A, B, C, and D mRNA levels among breast cancer subtypes are sta-
tistically significant (P < 0.001). 
Figure 24. KDM4A-D copy number alterations in breast cancer.1 High-level amplification and homozygous deletion of KDM4 
subfamily members in TCGA breast cancer dataset (n=976). Data are displayed with the Oncoprint tool from cBioPortal. Open 
access copyright permissions for this article permitted re-use of this figure from the American Journal of Cancer Research. 
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progression. Thus, examination of the association between copy number and mRNA 
expression of KDM4A, B, C and D was performed by using Spearman’s rank correlation 
in TCGA breast cancer specimens. Correlation between copy number and mRNA 
expression was strongest for KDM4C (R=0.61), followed by KDM4A (R=0.52); 
remaining KDM4 members had correlation coefficients less than 0.50 (R=0.44 for 
KDM4D, and R=0.28 for KDM4B) (Figure 25).  
Next, it was sought to determine whether the high-level amplification or 
expression level of each KDM4 member was related to breast cancer subtype. Of the 
TCGA breast cancer samples, 493 had subtype data available, including 8 normal-like, 
220 Luminal A, 121 Luminal B, 55 HER2+, and 89 basal-like breast cancers. Due to the 
small sample size (n=8) of the normal-like subtype, those samples were excluded from 
this analysis. KDM4C and KDM4D amplification was found to have the highest 
frequency (12.4% and 3.6%, respectively) in basal-like breast cancer. The highest 
frequency of KDM4A amplification (3.6%) was in HER2-subtype samples, whereas 
KDM4B amplification (3.3%) was highest in Luminal B breast cancer (Figure 26). To 
determine whether mRNA expression of each KDM4 subfamily member is associated 
with a specific subtype of breast cancer, the mRNA expression levels of KDM4A, B, C 
and D were compared across different subtypes of breast cancer specimens. Indeed, 
mRNA expression levels of KDM4A, C, and D were significantly higher in basal-like 
breast cancer (P=0.005, 6.01E-05, and 3.04E-07, respectively), whereas KDM4B 
mRNA was highly expressed in luminal breast cancer and less expressed in basal-like 
breast cancer (Figure 27).  
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Figure 25. KDM4A, B, C, and D mRNA expression (y-axis) versus copy number (x-axis) in 976 TCGA 
primary breast cancer samples.1 Amp: high-level amplification; Gain: low level gain; Hetloss: heterozygous 
deletion; and Homdel: homozygous deletion. Open access copyright permissions for this article permitted re-use 
of this figure from the American Journal of Cancer Research. 
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the gene. As shown in Figure S1, we found that 
KDM4C had the highest frequency (13.4%) of 
genetic alteration, including high-level amplifi-
cation, homozygous deletion, mutation, upreg-
ulation, and downregulation, whereas KDM4B 
had the lowest frequency (6.1%) of genetic 
alteration among the 976 TCGA breast cancer 
specimens. For KDM4C, 2.5% of samples had 
high-level amplification and 0.7% had homozy-
gous deletion, whereas 1.9% of samples had 
high-level amplification or homozygous deletion 
of KDM4A, B and D (Figure 1A). 
Correlations between gene expression and 
copy number have been used widely to priori-
tize driver oncogenes in human cancer, because 
mRNA expression can successfully translate 
the effect of elevated copy number to cancer 
initiation and progression. Thus, we examined 
the association between copy number and 
mRNA expression of KDM4A, B, C and D by 
using Spearman’s rank correlation in TCGA 
breast cancer specimens. We found that the 
correlation between copy number and mRNA 
expression was strongest for KDM4C (R=0.61), 
followed by KDM4A (R=0.52); remaining KDM4 
members had correlation coefficients less than 
0.50 (R=0.44 for KDM4D, and R=0.28 for 
KDM4B) (Figure S2). 
Next, we determined whether the high-level 
amplification or expression level of each KDM4 
member was related to breast cancer subtype. 
Of the TCGA breast cancer samples, 493 had 
subtype data available, including 8 normal-like, 
220 Luminal A, 121 Luminal B, 55 HER2+, and 
89 basal-like breast cancers. Due to the small 
sample size (n=8) of the normal-like subtype, 
those samples were excluded from this analy-
sis. KDM4C and KDM4D amplification was 
found to have the highest frequency (12.4% 
and 3.6%, respectively) in basal-like breast 
cancer. The highest frequency of KDM4A ampli-
fication (3.6%) was in HER2-subtype samples, 
whereas KDM4B amplification (3.3%) was high-
est in Luminal B breast cancer. To determine 
Figure 1. KDM4A-D copy number and expression levels in different sub-
types breast cancer. A. High-level amplification and homozygous deletion 
of KDM4 subfamily members in TCGA breast cancer dataset (n=976). 
Data are displayed with the Oncoprint tool from cBioPortal. B. Frequen-
cies of high-level amplification of KDM4A, B, C, and D in different subtypes 
of breast cancer. C. Expression levels of KDM4A, B, C, and D across five 
subtypes of breast cancer based on TCGA database. The differences in 
KDM4A, B, C, and D mRNA levels among breast cancer subtypes are sta-
tistically significant (P < 0.001). 
Figure 26. KDM4A-D high-level amplification frequencies in different subtypes of breast cancer.1 
Frequencies (%) of high-level amplification of KDM4A, B, C, and D in different subtypes of breast 
cancer. Open access copyright p rmissions for this article permitted re-use of this figure from the 
American Journal of Cancer Research. 
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the gene. As shown in Figure S1, we found that 
KDM4C had the highest frequency (13.4%) of 
genetic alteration, including high-level amplifi-
cation, homozygous deletion, mutation, upreg-
ulation, and downregulation, whereas KDM4B 
had the lowest frequency (6.1%) of genetic 
alteration among the 976 TCGA breast cancer 
specimens. For KDM4C, 2.5% of samples had 
high-level amplification and 0.7% had homozy-
gous deletion, whereas 1.9% of samples had 
high-level amplification or homozygous deletion 
of KDM4A, B and D (Figure 1A). 
Correlations between gene expression and 
copy number have been used widely to priori-
tize driver oncogenes in human cancer, because 
mRNA expression can successfully translate 
the effect of elevated copy number to cancer 
initiation and progression. Thus, we examined 
the association between copy number and 
mRNA expression of KDM4A, B, C and D by 
using Spearman’s rank correlation in TCGA 
breast cancer specimens. We found that the 
correlation between copy number and mRNA 
expression was strongest for KDM4C (R=0.61), 
followed by KDM4A (R=0.52); remaining KDM4 
members had correlation coefficients less than 
0.50 (R=0.44 for KDM4D, and R=0.28 for 
KDM4B) (Figure S2). 
Next, we determined whether the high-level 
amplification or expression level of each KDM4 
member was related to breast cancer subtype. 
Of the TCGA breast cancer samples, 493 had 
subtype data available, including 8 normal-like, 
220 Luminal A, 121 Luminal B, 55 HER2+, and 
89 basal-like breast cancers. Due to the small 
sample size (n=8) of the normal-like subtype, 
those samples were excluded from this analy-
sis. KDM4C and KDM4D amplification was 
found to have the highest frequency (12.4% 
and 3.6%, respectively) in basal-like breast 
cancer. The highest frequency of KDM4A ampli-
fication (3.6%) was in HER2-subtype samples, 
whereas KDM4B amplification (3.3%) was high-
est in Luminal B breast cancer. To determine 
Figure 1. KDM4A-D copy number and expression levels in different sub-
types breast cancer. A. High-level amplification and homozygous deletion 
of KDM4 subfamily members in TCGA breast cancer dataset (n=976). 
Data are displayed with the Oncoprint tool from cBioPortal. B. Frequen-
cies of high-level amplification of KDM4A, B, C, and D in different subtypes 
of breast cancer. C. Expression levels of KDM4A, B, C, and D across five 
subtypes of breast cancer based on TCGA database. The differences in 
KDM4A, B, C, and D mRNA levels among breast cancer subtypes are sta-
tistically significant (P < 0.001). 
Figure 27. KDM4A-D expression levels in different 
subtypes of breast cancer.1 Expression levels of 
KDM4A, B, C, and D across five subtypes of breast 
cancer based on TCGA database. The differences in 
KDM4A, B, C, and D mRNA levels among breast 
cancer subtypes are statistically significant  
(P < 0.001). Open access copyright permissions for 
this article permitted re-use of this figure from the 
American Journal of Cancer Research. 
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 KDM4C was validated to be amplified at high levels in 12.4% of basal-like 
tumors. Incorporating low level-gain (39 of 89 cases, 43.8%) leads to more than half of 
basal-like tumors with an increased KDM4C copy number. Furthermore, KDM4A, C, 
and D had high mRNA expression levels in basal-like breast cancer. High-level 
amplification and expression of KDM4A, C, and D tended toward mutual exclusivity 
(Figure 24). Thus, KDM4A, C, and D might individually contribute to the aggressive 
phenotypes of basal-like breast cancer. Taken together, these data indicate that 
amplification and overexpression of KDM4A, C, and D are more prevalent in 
aggressive, basal-like breast cancers, while KDM4B overexpression is more prevalent 
in ER+, luminal breast cancers.  
 
Expression of KDM4 demethylases and histone methylation marks in breast cancer cell 
lines 
Next, the relative mRNA and protein expression levels of KDM4A, B, C and D in 
a panel of breast cancer cell lines were examined (Figures 28 & 29). MCF10A, an 
immortalized but non-tumorigenic breast epithelial cell line, was used as the control. 
Quantitative RT-PCR (qRT-PCR) assays were used to measure the mRNA expression 
level of KDM4A, B, C and D in 17 breast cancer cell lines, including nine basal-like, two 
HER2+, and six Luminal lines (Figure 28). To determine KDM4A, B, C and D protein 
abundance more precisely relative to their histone demethylase function, nuclear 
extracts from eight breast cancer cell lines and MCF10A were isolated and probed with 
antibodies that recognize KDM4A, B, C and D (Figure 29). KDM4A mRNA was found to 
be overexpressed in several ER+ luminal cell lines (such as HCC1428) and basal-like 
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cell lines (such as MDA-MB-468). KDM4B was strikingly overexpressed at the mRNA 
level in luminal cell lines, yet nuclear protein was also abundant in basal-like lines, such 
as Colo824 (Figure 29).  
Consistent with the data from primary breast cancer specimens and previous 
findings, KDM4C is highly overexpressed in a set of basal-like breast cancer cell lines, 
including HCC1954 and Colo824, which both contain high-level KDM4C gene 
amplification (Note: Expression analysis indicate that the HCC1954 line belongs to the 
basal-like subtype even though it contains HER2 amplification).131 Strikingly, 
immunoblot analysis did detected high levels of KDM4C protein expression in nuclear 
extracts from HCC1954 and Colo824 breast cancer cell lines (Figure 29). Similar to 
KDM4A, KDM4D is also overexpressed at the mRNA level in various ER+ luminal and 
basal-like cell lines. Interestingly, HCC1954 and Colo824 cells also showed KDM4D 
(11q21) gene amplification. However, KDM4D protein in these nuclear extracts was 
likely ubiquitously expressed in ER+ and basal breast cancers as well as MCF10A cells 
(Figure 29).  
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Figure 28. KDM4 subfamily mRNA expression in breast cancer cell lines.1 
mRNA expression levels of KDM4 demethylases in a panel of breast cancer cell 
lines were determined by qRT-PCR. mRNA expression levels in the MCF10A cells, 
an immortalized but nontumorigenic breast epithelial cell line, were arbitrarily set as 
1. Relative expression levels in breast cancer cell lines are shown as fold changes 
compared with that of MCF10A cells. *The HCC1954 line belongs to the basal-like 
subtype even though it contains HER2 amplification. Thanks to Qin Ye for help with 
parts of this figure. 
Open access copyright permissions for this article permitted re-use of this figure 
from the American Journal of Cancer Research. 
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Figure 29. KDM4 subfamily protein expression in breast cancer cell 
lines.1 KDM4A, B, C, D and Estrogen Receptor (ER) protein levels were 
analyzed by western blot in eight breast cancer cell lines and the MCF10A 
non-tumorigenic mammary epithelial cell line. Total H3 was used as the 
loading control. Thanks to Qin Ye for help with parts of this figure. 
Open access copyright permissions for this article permitted re-use of this 
figure from the American Journal of Cancer Research. 
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RESULTS: 
 
CHARACTERIZATION OF THE MOLECULAR PROFILE OF GENE 
ASSOCIATED WITH TIME TO BREAST CANCER IN BENIGN BREAST 
LESIONS 
 
 
To identify networks and diseases associated with genes significantly associated 
with time to breast cancer, with help from the Biostatistics Core at Karmanos Cancer 
Institute, IPA mapped the 18,749 transcripts to 8,075 unique genes (Figure 19). Next, 
1,805 of these genes (p-value<0.01) were analyzed to identify genetic networks and 
functional classifications of genes associated with time to breast cancer diagnosis. 
Overall, 80.7% of these genes (1,454 of 1,802 genes) were found to be up-regulated in 
association with shorter time to breast cancer diagnosis. Select significant genes were 
subsequently measured on Nanostring technology for all 36 samples in the cohort by 
collaborators at Mayo Clinic Cancer Center in Jacksonville, Florida, to validate the 
expression level differences observed by microarray (Figure 30). 
Inflammatory disease ranked as the top disorder (p-value = 0.0483-0.00001) of 
molecules significantly associated with shorter time to breast cancer diagnosis (data not 
shown). Gene expression and organ morphology, cellular development, and cell 
morphology, were the top networks and associated network functions of genes 
associated with shorter time to breast malignancy (Figure 31).  
To gain further insight into the top network of gene expression and organ 
morphology, molecules were mapped using IPA software and are shown in Figure 32. 
Of the eleven genes regulated by the estrogen receptor in this network, ten (90.9%) 
were found to be significantly associated with shorter time to breast cancer diagnosis. 
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Additional analysis revealed that of these ten molecules, the majority (70%; 7 of 10 
molecules) were found to be up-regulated in association with shorter time to breast 
cancer diagnosis (CDH9, NCAM2, CLDN23, CNNM1, CDH12, PCDH20, FGFR3) 
(Figure 32).  
Examination of the top canonical pathways and overlap of pathway molecules 
revealed significant overlap with 25.0% of molecules in the lipid antigen presentation by 
CD1 pathway (p-value = 0.0028) (Figure 33). Notably, this immune strategy uses CD1, 
a conserved family of major histocompatibility complex-like glycoproteins that capture 
lipid antigens for presentation to T-lymphocytes and contribute to innate and adaptive 
immune responses. Significant findings also included overlap with 18.4% of estrogen 
biosynthesis pathway molecules (p-value=0.0078), consistent with the synthesis of 
steroid hormones estrone and estradiol in breast tissue that is critical for development 
and function, as well as induction of tumor growth. 
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Figure 30. Differentially expressed gene custom code set (gene symbol, gene name, accession number, and target region) 
for Nanostring analysis. Samples were loaded onto the Nanostring PrepStation for processing, and placed into the nCounter 
cartridge. The cartridge was transferred to the nCounter digital analyzer for image capture and data acquisition of fluorescent 
reporters. Measurements were taken at high sensitivity with 555 FOV. The positive controls measured on each array were used to 
normalize the observed nanostring reads, using linear regression to estimate the adjustment factor for each sample. The 
agreement between normalized Affymetrix probe and Nanostring gene expression values was analyzed by Spearman correlation 
using the software R. Nanostring validation was performed by collaborators at Mayo Clinic, Jacksonville, Florida.  
Boldface text indicates a correlation p-value of < 0.05. 
 
  
Gene 
Symbol Entrez Gene Name Accession Number 
Target 
Region 
ARF1 ADP ribosylation factor 1 NM_001024227.1 1371-1470 
CASP14 caspase 14 NM_012114.2 627-726 
CD59 CD59 molecule NM_000611.4 731-830 
CEBPA CCAAT/enhancer binding protein alpha NM_004364.2 1321-1420 
DEAF1 DEAF1, transcription factor NM_021008.2 1025-1124 
EGR2 early growth response 2 NM_000399.3 1892-1991 
ESR1 estrogen receptor 1 NM_000125.2 1596-1695 
ESR2 estrogen receptor 2 NM_001214903.1 167-266 
FGFR3 fibroblast growth factor receptor 3 NM_022965.2 3171-3270 
GNB1 G protein subunit beta 1 NM_002074.2 2166-2265 
GRB2 growth factor receptor bound protein 2 NM_002086.4 413-512 
HSD17B1 hydroxysteroid (17-beta) dehydrogenase 1 NM_000413.2 1575-1674 
HUNK hormonally up-regulated Neu-associated kinase NM_014586.1 1281-1380 
ITCH itchy E3 ubiquitin protein ligase NM_001257138.1 439-538 
KAT2B lysine acetyltransferase 2B NM_003884.3 1221-1320 
KDM4C lysine demethylase 4C NM_001146694.1 2033-2132 
LCK LCK proto-oncogene, Src family tyrosine kinase NM_005356.2 1261-1360 
LY6E lymphocyte antigen 6 complex, locus E NM_002346.2 381-480 
PAX6 paired box 6 NM_000280.3 1174-1273 
POU5F1 POU class 5 homeobox 1 NM_002701.4 1226-1325 
RHOA ras homolog family member A NM_001664.2 1231-1330 
RIPK3 receptor interacting serine/threonine kinase 3 NM_006871.3 1541-1640 
RNF11 ring finger protein 11 NM_014372.4 725-824 
RUNX3 runt related transcription factor 3 NM_004350.1 2086-2185 
SALL4 spalt-like transcription factor 4 NM_020436.3 3225-3324 
SOX11 SRY-box 11 NM_003108.3 5651-5750 
TBP TATA-box binding protein NM_001172085.1 588-687 
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 NM_021141.3 833-932 
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Figure 31. Top three networks, associated network functions, molecules in network, and number of focus 
molecules significantly associated with shorter time to breast cancer diagnosis among thirty-six black 
women with benign breast lesions. Boldface text indicates genes that were available in the dataset and significantly 
associated with shorter time to breast cancer diagnosis. 
 
 
  
Networks and 
Associated Network 
Functions 
Molecules in Network 
Number of 
Focus 
Molecules 
Gene Expression, 
Organ Morphology 
ABCA4, ACTB, ADCY, ASB9, BCL11B, BRF1, 
C9, CASP14, CD58, CD59, CDH9, CDH12, 
CLDN23, CNNM1, estrogen receptor, FGFR3, 
GNAI2, GNB1, GNGT1, GTF2E1, HIST1H1A, 
Hsp27, Hsp70, LCK, LTB, LY6E, MAP1B, 
NCAM2, PCDH20, SOX11, TAF2, TAF5, TAF9, 
TAF1A, TBP. 
31 
Cell Death and 
Survival, Cellular 
Growth and 
Proliferation, Cellular 
Development 
ACTR2, AP2B1, CCL4L1/CCL4L2, CEBPA, 
EOMES, EPHX1, FCER1G, FSH, GAPDH, 
GRB2, HELZ, HSD17B1, Lh, LST1, MIXL1, 
PAF1, PAX6, POU5F1, PTP4A1, RAB14, 
RAB1A, RALGAPA1, RBBP4, RIPK3, RNA 
polymerase II, SALL4, SERPINI1, SLC25A3, 
Smad2/3, SOD2, STS, TAC3, TNFRSF9, VHL, 
XRCC5. 
31 
Cell Morphology, 
Organismal 
Abnormalities 
ANO3, ARF1, BCR, CAPNS1, CD63, Creb, 
DYNLL1, EDARADD, GPR34, HLA-DMB, HPF1, 
IL1RL2, KSR2, LITAF, mir-506, MIR17HG, Mlc, 
MYLK, NFkB (complex), NLRP2, OTUB2, 
PTPRS, RAB31, RAP1GAP, RFTN1, RGS5, 
RHOA, RNF11, Rock, RTF1, SLC8A1, SPIB, 
SUMO4, TRPC6, UBE2V1. 
31 
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Figure 32. Network of gene expression and organ morphology. Red indicates a log hazard ratio (LHR) of > 
1; green color indicates a LHR of < -1. Grey indicates the gene was not differentially expressed and white 
indicates the gene was not found to be statistically significant in the dataset. The legend indicates shapes for 
genes with known functions. Solid lines indicate a direct relationship and dashed lines represent an indirect 
relationship. Figure generated using Ingenuity Pathway Analysis software. 
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Figure 33. Top canonical pathways and overlap between pathway molecules and genes in benign breast 
lesions significantly associated with shorter time to breast cancer diagnosis. 
  
Pathway p-value Overlap Overlap Molecules 
Lipid Antigen 
Presentation by CD1 0.0028 25.0% 
CD3E, PDIA3, AP2B1, FCER1G, 
PSAP, CANX. 
Retinoate 
Biosynthesis I 0.0106 19.4% 
SDR9C7, ALDH1A3, ALDH1A2, 
RDH16, AKR1C4, AKR1B10. 
Estrogen Biosynthesis 0.0078 18.4% 
CYP4F8, CYP1A1, CYP4B1, 
HSD17B12, AKR1C4, HSD17B1, 
CYP2C8. 
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DISCUSSION 
 
Using the Detroit benign breast disease cohort, this analysis of molecular 
precursors among thirty-six black women with benign breast lesions who subsequently 
developed breast cancer identified genes involved in inflammatory disease and 
estrogen biosynthesis associated with shorter time to breast cancer diagnosis. These 
findings are novel in that this study is the first to identify potential molecular precursors 
associated with shorter time to breast cancer diagnosis among black women with 
benign breast lesions.  
The inflammatory state of premalignant and malignant lesions is considered an 
enabling characteristic to promote tumor progression.151 The top disorder associated 
with the significant gene set was inflammatory disease, a process where tissues of the 
body elicit a biological response to pathogens and damaged cells. Epidemiological 
studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs) contribute to the 
reduction of breast cancer risk,75 and Griffith et al. recently published that black women 
diagnosed with breast cancer demonstrated increased inflammation compared to black 
controls without a history of disease.152 Chronic inflammation has been shown to drive 
breast cancer pathologies, with recent studies beginning to investigate epigenetic 
regulation of inflammation, particularly the role of histone lysine demethylases, to target 
tumorigenic mechanisms.153-155  
Strikingly, histone lysine demethylase 4C (KDM4C) was the top-upregulated 
molecule in this analysis, with increased expression of this gene associated with shorter 
time to breast cancer diagnosis. Previous studies have demonstrated that KDM4C 
serves as a transforming oncogene and undergoes genetic alterations at a high 
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frequency in breast cancers.1,138,156 KDM4C is amplified and overexpressed in 
aggressive basal-like breast cancers, and associated with poor patient prognosis. 
KDM4 demethylases function extensively in multiple cellular events throughout 
organismal development and homeostasis.113-115,140,142,144,146,157-161 Despite the recent 
discovery that the KDM4 subfamily plays an essential role in regulating gene expression 
and chromatin architecture via H3K9 and H3K36 demethylation,157 there is still much to 
learn about how KDM4 proteins are recruited to genomic loci, how they modulate 
histone demethylation and subsequently activate specific downstream targets in 
different cell types. Moreover, it is clear that KDM4 proteins cooperate in similar 
macromolecular complexes and processes,158,160-162 yet the redundancies and 
interactions between them are still not well understood.  
Considering the enormous potential of these epigenetic master regulators in 
modulating gene transcriptional programs, it is not surprising that their alterations are 
implicated in human diseases, particularly in cancer.1,113,114,144 Utilizing The Cancer 
Genome Atlas breast cancer database and cell line models, KDM4A, B, C and D gene 
amplification and expression were analyzed relative to different breast cancer subtypes. 
Consistent with previous findings, KDM4C amplification had the highest frequency 
(12.4%) in basal-like breast cancer compared with other subtypes.131 Furthermore, high 
expression of KDM4A, C, and D was found in the basal type and KDM4B was found in 
ER+ luminal-type breast cancers.  
Within the KDM4 subfamily, KDM4A, B, and C show a high degree of homology 
in sequence and domain organization.3 Although KDM4 demethylases all catalyze via 
the same demethylation reaction, recent evidence indicates that their normal cellular 
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functions are not completely redundant. Possible reasons for these unique functions 
are: (1) a distinct pattern of intracellular location, (2) cell-type-specific expression, (3) 
selective recruitment of the different KDM4 demethylases to their target genes, and (4) 
demethylase specific non-histone proteins.113-115,140,157-159 Indeed, recent studies 
revealed that KDM4A is equally present in the cytoplasm and nucleus, KDM4B is more 
prevalent in the nucleus, and KDM4C strongly associates with chromatin.159,163 It was 
also reported that protein levels of KDM4A and B, but not KDM4C, are highly regulated 
by ubiquitination and the proteasome since KDM4A and B are direct substrates of the 
E3 ubiquitins RNF8 and RNF168.160 In contrast, inositol pyrophosphates regulate 
KDM4C-dependent histone demethylation.164 More recent studies showed that KDM4B 
and C have distinct and combinatorial functions in mouse embryonic stem cell 
identity.157 Most likely, the four KDM4 subfamily members have substantially 
overlapping but not completely redundant functions, and their functions are cell-type 
specific and context-dependent. Because epigenetic changes are reversible and histone 
demethylases are druggable,128,144,165-167 despite challenges of overlapping targets they 
remain promising therapeutic targets for chemoprevention and intervention strategies. 
Estrogen biosynthesis is a critical mechanism to produce estrogens involved in 
regulation of the female reproductive system. The synthesis of estrogen is widely 
regulated by the aromatase enzyme, a member of the cytochrome P450 superfamily.168 
Aromatase is comprised of a regulatory region of ten tissue-specific promoters for local 
estrogen biosynthesis in both normal physiological and breast cancer conditions.169 
Estrogen biosynthesis was identified as one of the top canonical pathways of 
differentially expressed genes. Higher expression levels of four cytochrome P450 family 
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member genes (CYP4F8, CYP1A1, CYP4B1, CYP2C8) in the estrogen biosynthesis 
pathway were significantly associated with shorter time to breast cancer diagnosis. 
Further, most estrogen-mediated signaling pathways are estrogen receptor-dependent 
and change during the ageing process.170,171 This analysis also revealed that ten genes 
regulated by the estrogen receptor, including the increased expression of fibroblast 
growth factor receptor 3 (FGFR3), were associated with shorter time to breast cancer 
diagnosis. Notably, previous studies have demonstrated that FGFR3 plays a critical role 
in breast cancer development and response to endocrine therapy.172,173 FGFR3 
activation stimulates activation of the mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K) signaling pathways in vitro, and reduces sensitivity of 
breast cancer cells to tamoxifen.173,174  
Activation of estrogen signaling pathways through inflammation-mediated 
upregulation of aromatase is critical to breast carcinogenesis. The severity of breast 
inflammation correlates with aromatase activity, as increased aromatase levels lead to 
enhanced estrogen biosynthesis and progesterone receptor upregulation.175 Risk of 
developing estrogen and progesterone receptor-positive breast cancers are significantly 
increased among overweight and obese women,176 as obesity is also associated with 
inflammation via elevated levels of circulating pro-inflammatory mediators that promote 
growth and tumorigenesis.177,178 Dandona et al. demonstrated that increased levels of 
pro-inflammatory mediators correlate with poor prognosis among obese patients with 
breast cancer.179 Regardless of breast cancer subtype, overweight and obese women 
suffer from greater tumor burden and worse disease-related outcomes versus leaner 
counterparts.180,181 Overweight and obesity rates are nearly 1.5 times higher among 
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black adults compared to whites,182 and black women have been shown to have the 
highest BMI among gender and race/ethnicity subgroups.183 Aligned with this evidence, 
genes that are involved in inflammatory disease and estrogen biosynthesis were found 
to be associated with shorter time to breast cancer diagnosis among the cohort of black 
women, of which the majority was found to be overweight and obese. 
The indirect association of the estrogen receptor and DNA influences the activity 
of transcription factors, and has been found to promote breast cancer cell proliferation 
through co-regulation of key cell cycle regulators.184,185 It was noted that cellular growth 
and proliferation, death and survival, and development, also ranked as the top canonical 
pathway for genes associated with a shorter time to breast cancer diagnosis in benign 
lesions. Profiling the molecular characteristics of benign breast lesions from black 
women who subsequently developed breast cancer identified DEAF1, a transcription 
factor, as the top-downregulated molecule in this analysis. Prior reports have 
discovered that DEAF1 contributes to the proliferation of mammary epithelial cells and 
ductal side-branching to regulate normal development and breast cancer.186,187 Breast 
cancer most commonly arises from the mammary ductal epithelium, and consists of 
tumors with various pathologic and molecular characteristics—which are determinants 
for metastatic behavior and clinical outcome. Previous studies demonstrated that black 
women with a history of benign breast disease have a higher risk of subsequent breast 
cancer.2,188 Thus, further work is warranted to analyze the molecular and pathological 
characteristics of benign breast lesions and subsequent breast cancers developed 
among these black women to evaluate potential precursor molecules and biomarkers 
for increased surveillance and detection of cancer at early stages of disease. 
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The review of medical records to collect data on body mass index and additional 
information on important breast cancer risk factors, including history of tobacco use, age 
at menarche, and menopausal status, is a strength of this study. Complete information 
on breast density was unable to be collected, which would have provided a more 
detailed assessment of the biopsy tissue microenvironment. Yet linkage of benign 
breast disease cases to the Metropolitan Detroit Cancer Surveillance System (MDCSS) 
for identification of subsequent breast cancer development is another strength, as it 
allowed for detailed patient follow-up and identification of pathologically-verified cases. 
Use of the Affymetrix platform for gene expression profiling of benign FFPE samples 
and data processing also provided accurate interpretation of results.189 Limitations of 
sample validation include using Nanostring technology to confirm these results, given 
the limited target regions of probes for genes. A larger sample size for transcriptome 
profiling of benign breast lesions is needed to further examine the predictive value of 
these molecular precursors to predict time to cancer, and additional studies are called 
for to see if these molecular markers are associated with subsequent breast cancer risk.  
Taken together, these findings elucidate molecular precursors of benign breast 
lesions in black women that are associated with shorter time to breast cancer. While 
breast cancer survival rates have improved over the last two decades, breast cancer 
still accounts for 14% of all cancer-related deaths among women annually.8 
Identification of top canonical pathways and networks of genes associated with shorter 
time to breast cancer diagnosis can provide further insight into critical mechanisms of 
tumorigenesis and progression to a malignant state. Additional studies analyzing the 
molecular profiles of benign breast and breast cancer lesions among women, 
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particularly the disparate black population, can contribute to improvements in 
surveillance and detection, and ultimately improved patient survival. 
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PATIENTS AND METHODS 
 
Study design and patient cohort 
This study population comprises patients selected from the metropolitan Detroit 
benign breast disease (BBD) cohort, which has been described previously by Cote et 
al.2 The BBD cohort is composed of 3,759 women aged 21 to 88 years who self-
reported African American/black race from metropolitan Detroit, Michigan, and who had 
been diagnosed with BBD between 1997 and 2010 at hospitals and clinics associated 
with the Detroit Medical Center and Wayne State University Department of Pathology. 
Exclusion criteria included: a previous breast biopsy, a history of invasive or in situ 
breast carcinoma prior to, or within 6 months, of the BBD biopsy, unilateral or bilateral 
mastectomy prior to or at diagnosis, prior breast reduction surgery, lipoma, fat necrosis, 
epidermal cysts, hematoma, accessory structure, phyllodes tumor, or a lymph node 
biopsy with no breast tissue.188 Using the Metropolitan Detroit Cancer Surveillance 
System (MDCSS), a founding member of the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) program which has been continuously 
collecting population-based cancer data since 1973,7 information on subsequent 
development of breast cancer was obtained.2 
Thirty-six women selected based on tissue availability from the benign breast 
disease cohort who subsequently developed breast cancer with available benign breast 
lesion tissue blocks comprised this study population. The distribution of clinical and 
demographic characteristics of these patients was described using percentages. All 
study procedures were approved by the Wayne State University Institutional Review 
Board. 
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Histology review 
Biopsy review has been previously described by Cote et al.2 Lesions were 
classified on Dupont and Page criteria101 into three categories: non-proliferative 
disease, proliferative disease without atypia, or proliferative disease with atypia (atypical 
hyperplasia). Pathological features assessed for each biopsy included: apocrine 
metaplasia, atrophy, calcifications, columnar alterations, cyst, ductal ectasia, ductal 
hyperplasia, fibroadenoma, fibrosis, intraductal papilloma, mucocele-like lesions, lobular 
hyperplasia, radial scar, sclerosing adenosis (Figure 12). The distribution of pathological 
characteristics of breast lesions/biopsies was described using percentages. 
 
Cumulative incidence 
The cumulative incidence for developing breast cancer was calculated using R 
statistical software, package ‘cmprsk’.190,191 Time to breast cancer diagnosis was 
evaluated considering behavior as a competing risk (in-situ versus invasive disease). All 
women in the metropolitan Detroit BBD cohort were evaluated in this analysis. Of the 
3,759 black women with benign breast disease, 217 women developed breast cancer 
(63 in-situ cancers and 154 invasive cancers). 
 
Extraction of RNA and gene expression profiling 
RNA was extracted from 97 formalin-fixed, paraffin-embedded (FFPE) benign 
breast samples from the thirty-six black women using the High Pure RNA Paraffin Kit 
(Roche Diagnostics, Germany) by collaborators at Mayo Clinic Cancer Center in 
Jacksonville, Florida. RNA quantity and quality were assessed using the ND-1000 
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Spectrophotometer (Nanodrop, Wilmington, Delaware). One sample per patient was 
utilized for further analysis if the optical density 260/280 ratio was ≥1.8, the total RNA 
yield was ≥500 ng, and based on the highest DV200 value as a measure of RNA 
quality. Extracted RNA was labeled and hybridized to the Affymetrix human 
transcriptome array 2.0 (HTA 2.0) exon array chip containing > 6.0 million distinct 
probes covering 44,699 protein-coding genes (transcript clusters) and 22,829 non-
protein-coding genes according to manufacturer’s protocol at the Mayo Clinic Cancer 
Center. 
 
Transcriptomic and ingenuity pathway analyses 
Sample probe gene expression values were exported from Affymetrix and 
imported into the software R190 for normalization, additional quality control, and analysis 
using the Bioconductor ‘oligo’ software package.192 Working with the Biostatistics Core 
at Karmanos Cancer Institute, data were background corrected using the robust multi-
array average algorithm, normalized using quantile normalization, and summarized 
using median polish. Cox proportional hazards models were used to determine which 
transcripts were associated with time-to-breast cancer.  
Log hazard ratios (LHR) and standard error (SE) were estimated for each 
transcript after adjusting for age at breast biopsy (years), and benign breast biopsy 
overall impression (non-proliferative disease, proliferative disease without atypia, 
proliferative disease with atypia). LHRs > 0 indicate that a gene expression increase is 
associated with an earlier time-to-cancer diagnosis. LHRs < 0 indicate that a gene 
expression decrease is associated with an earlier time-to-cancer diagnosis. The 
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microarray data discussed in this publication will be deposited into the NCBI's Gene 
Expression Omnibus.  
Transcripts with a p-value < 0.05 and a LHR of at least 1 (absolute value) were 
considered to be significant (Figure 19). Genes that were statistically significant at the 
0.01 level were subsequently entered into Ingenuity Pathway Analysis (IPA) software 
(Ingenuity Systems, Mountain View, California) with the help of the Karmanos Cancer 
Institute Biostatistics Core to determine the most significantly enriched functions, 
networks, diseases, and pathways. 
 
RNA validation and correlation analysis 
Twenty-eight statistically significant genes (Figure 30) and ten housekeeping 
genes were submitted to create a custom code set for Nanostring technology analysis 
to confirm the results on alternative technology. The assay was performed at Mayo 
Clinic Cancer Center in Jacksonville, Florida, according to manufacturer’s protocol 
(nCounter XT CodeSet Gene Expression Assay). Briefly, 100ng of extracted RNA was 
hybridized with the Reporter CodeSet and Capture ProbeSet for 18 hours at 65°C. 
Samples were loaded onto the Nanostring PrepStation for processing, and placed into 
the nCounter cartridge. The cartridge was transferred to the nCounter digital analyzer 
for image capture and data acquisition of fluorescent reporters. Measurements were 
taken at high sensitivity with 555 FOV. The positive controls measured on each array 
were used to normalize the observed nanostring reads, using linear regression to 
estimate the adjustment factor for each sample with help from the Biostatistics Core at 
the Karmanos Cancer Institute in Detroit, Michigan. The agreement between normalized 
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Affymetrix probe and Nanostring gene expression values was analyzed by Spearman 
correlation using the software R. 
 
Cell culture  
The cultures for the SUM series of breast cancer cell lines and nontransformed 
human mammary epithelial cell MCF10A line have been described in detail 
previously.193,194 The Colo824 cell line was obtained from DSMZ, the SUM cell lines 
were obtained from Dr. Stephen P. Ethier, and all other cell lines in this study were 
obtained from ATCC (Manassas, VA). These lines were maintained in RPMI with 10% 
FBS (Atlanta Biologicals, Flowery Branch, GA, USA) according to DSMZ and ATCC 
protocols.  
 
The Cancer Genome Atlas (TCGA) data for breast cancer  
The DNA copy number, mutation, and RNA sequencing datasets of 976 breast 
cancer samples used in this research were obtained from the cBio Cancer Genomics 
Portal.148,149 The copy number of each histone lysine demethylase was generated from 
the copy number analysis algorithms GISTIC (Genomic Identification of Significant 
Targets in Cancer) and categorized as copy number level per gene: “-2” is a deep loss 
(possibly a homozygous deletion), “-1” is a heterozygous deletion, “0” is diploid, “1” 
indicates a low-level gain, and “2” is a high-level amplification.  
For mRNA expression data, the relative expression of an individual gene and the 
gene expression distribution in a reference population were analyzed. The reference 
population was either all tumors that are diploid for the gene in question, or, when 
available, normal adjacent tissue. The returned value indicates the number of standard 
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deviations away from the mean of expression in the reference population (Z-score). 
Somatic mutation data were obtained from exome sequencing.148,149 The breast cancer 
subtype information was from a previous publication and the cBio Cancer Genomics 
Portal.18,148,149 
 
Semiquantitative RT-PCR reactions  
mRNA was prepared from human breast cancer cell lines and the MCF10A cell 
line by using an RNeasy Plus Mini Kit (QIAGEN). mRNA was mixed with qScript cDNA 
SuperMix (Quanta Biosciences, Gaithersburg, MD, USA), then converted into cDNA 
through a reverse-transcription reaction for real-time PCR reactions. Primer sets for 
genes of interest were ordered from Life Technologies (Carlsbad, CA, USA). A PUM1 
primer set was used as a control. Semiquantitative RT-PCR was done using the 
FastStart Universal SYBR Green Master (Rox) (Roche Diagnostics Indianapolis, IN, 
USA).  
 
Immunoblotting and antibodies  
Whole cell lysates were prepared by scraping cells from the dishes into cold 
RIPA lysis buffer. Nuclear protein extracts from breast cancer cells and the MCF10A 
cells were prepared with an NE-PER Nuclear Protein Extraction Kit (Thermo Scientific, 
Rockford, IL, USA). Histone proteins from cells were isolated with the EpiQuik Total 
Histone Extraction Kit (Epigentek, Farmingdale, NY, USA). Protein content was 
estimated with the Bradford method.  
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A total of 20-100µg of total cell lysate was resolved by SDS-PAGE and 
transferred onto PVDF membrane. Antibodies used in the study included anti-KDM4D 
(Abcam ab93694, Cambridge, MA, USA), anti-KDM4B and C (Bethyl Laboratories 
A301-478A, Montgomery, TX, USA), anti-KDM4A, anti-H3, anti-H3K4me2, anti-
H3K4me1, anti-H3K9me1, anti-H3K36me3, anti-H3K36me2 (Cell Signaling, Danvers, 
MA, USA), anti-H3K4me3, anti-H3K9me3, and anti-H3K36me1 (Active Motif, Carlsbad, 
CA, USA).  
 
Statistical analysis for KDM4 studies 
Statistical analyses were performed using R software (http://www.r-project.org) 
and Stata.190,195 The correlations between copy numbers and mRNA levels of each 
histone lysine demethylase from 976 sequenced breast cancer specimens were 
analyzed using Spearman, Kendall, and Pearson correlation tests. The Spearman and 
Kendall tests are rank correlations: the Spearman coefficient relates the two variables 
while conserving the order of data points, and the Kendall coefficient measures the 
number of ranks that match in the data set. Although the Pearson correlation coefficient 
is the most widely used, it was deemed the least relevant to this study, as it measures 
only the strength of linear relationships and ignores all others. The “cor” function in R 
statistical software was used for computation, specifying in the code which type of test 
was desired (Spearman, Kendall, or Pearson). The difference in mRNA expression level 
for each histone lysine demethylase between the basal-like and the other cancer 
subtypes was calculated using Student’s t-test.  
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CHAPTER 4. GENERAL DISCUSSION 
Each year, over 1.5 million women undergo breast biopsies.94,95 Among these 
women, black individuals are more likely to have been referred for biopsy as follow-up 
from recommended mammograms, even despite lower rates of screening.196 While the 
majority of these biopsies performed result in benign findings,96 the pathological 
characteristics of some of these benign breast lesions still confer an increased risk of 
subsequent breast cancer diagnosis in white and black populations.2,99 These 
pathological features, including columnar alterations, fibroadenoma, sclerosing 
adenosis, cysts, and calcifications, contribute to the categorization of the benign breast 
lesion into loose groups for an overall impression according to Dupont and Page 
criteria,101 and are highly prognostic for breast cancer risk in populations of black 
women.2,188 This work is especially important given the racial disparities that exist in 
breast cancer incidence and survival, where black women are more likely to develop 
young-onset breast cancer with the disease diagnosed at more aggressive clinical 
stages.6,8 
Identification of women at the highest risk of disease has clinical implications, 
including: increased surveillance, diagnosis at early stage of malignancy, 
chemoprevention and intervention, and ultimately, improved survival outcomes. The 
development of risk prediction models to assess cancer risk on a personalized patient 
basis began in the 1990s. Perhaps the most appropriate model to predict invasive 
breast cancer risk for black women is the recently established CARE model that is 
tailored to this high-risk racial/ethnic population.197 Specific variables used to provide 
breast cancer risk estimates in the CARE model include: number of first-degree 
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relatives with a history of breast cancer, menarche age, age at first live birth, current 
age, and number of previous benign breast biopsies.197 While this model takes into 
account the number of previous benign breast biopsies, there is no incorporation of 
detailed pathological or molecular findings from breast biopsies. Further, few models 
consider benign breast pathological findings in risk prediction, and at best construct 
analyses based on the overall impression of the benign breast lesion. It is important to 
note there are limitations associated with pathological impressions, including differences 
in histological spectra and clinical manifestations of these lesions. Therefore, molecular 
findings among benign breast lesions that predict shorter time to breast cancer 
diagnosis could be instrumental to the improvement of breast cancer risk 
characterization among black women with a history of benign breast disease. 
Profiling the clinicopathology and molecular characteristics of benign breast 
lesions among black women who subsequently developed breast cancer in the Detroit 
cohort provides insight into both the histological and genomic scopes of benign breast 
disease, particularly in an understudied population with poor survival outcomes. These 
analyses identified the top up-regulated genes, including histone lysine demethylase 4C 
(KDM4C), pathways, diseases, and networks, including inflammation and estrogen 
biosynthesis, that are associated with a shorter time to breast cancer. These findings 
warrant further investigations to elucidate the dysregulation and molecular mechanisms 
of these modulators that contribute to breast carcinogenesis. 
The clinical implications of these molecular findings are also a paradigm for 
clarifying future risk of breast cancer development and shorter time to breast cancer 
diagnosis among black women with benign breast disease. Stratifying the risk for 1.5 
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million women who undergo breast biopsies annually is critical to identify those at 
highest risk of subsequent malignancy who could be best served with allocation of 
additional interventions and clinical management, as breast cancer ranks as the second 
leading cause of cancer related deaths annually in the United States.8 Elucidation of the 
biological basis of disparity in this high-risk population can contribute to ultimately 
understanding critical biological differences in patient prognosis. 
On a molecular level, breast cancer progression is a complex, multifactorial 
process traditionally viewed as the stepwise accumulation of genetic alterations. 
Furthermore, through the use of next-generation sequencing, it has become apparent 
that vital epigenetic regulators, such as histone methyltransferases and demethylases, 
undergo genetic alterations at a high frequency in aggressive breast cancer. Together, 
these chromatin modifications play critical roles in controlling transcription, chromatin 
architecture, and cellular differentiation. However, the genomic landscape and clinical 
significance of histone lysine demethylases in breast cancer remain poorly 
characterized.  
Dysregulation of the KDM4 demethylases has been documented in a variety of 
cancers, including lymphoma, medulloblastoma, and breast, prostate, colorectal, lung, 
gastric, esophageal, and renal cancers.1,131,132,134,139,166,198,199 The KDM4 demethylases, 
A, B, C, and D, were the first identified demethylases to act on tri-methylated 
lysines.133,143 Given these data and the finding that KDM4C was the top up-regulated 
molecule associated with shorter time to breast cancer diagnosis in benign breast 
lesions of black women, a meta-analysis of KDM4A, B, C and D in breast cancer was 
conducted and identified associations among recurrent copy number alterations, gene 
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expression and breast cancer subtypes. KDM4A, C and D are also significantly 
overexpressed in basal-like breast cancer, whereas KDM4B overexpression is more 
dominant in estrogen-receptor-positive, luminal breast cancer. These findings 
demonstrate genetic amplification and overexpression of the KDM4 demethylases in 
different subtypes of breast cancer, and provide information regarding the genomic and 
transcriptomic alterations of the KDM4 subfamily in different subtypes of breast cancer 
for a better understanding into the mechanisms of breast carcinogenesis. 
Using a large-scale cancer genomics data set, four KDM genes (KDM1B, 
KDM4C, KDM5A, and JARID2) were highly amplified (>10%) and overexpressed in 
basal-like breast cancer.156 Basal-like breast cancers are generally triple-negative, 
defined by lack of estrogen receptor, progesterone receptor, and HER2 oncoprotein 
expression.17 Basal-like tumors are associated with higher rates of metastasis and 
death, and given the lack of effective molecularly targeted therapies developed, the 
treatment for basal breast cancer consists of standard chemotherapy regimens.17,18 
Thus, the establishment and validation of novel therapeutic strategies that inhibit 
progression of breast cancer remains a primary challenge. Since histone methylation is 
reversible and demethylases are druggable targets, histone lysine demethylase 
inhibitors may serve as a novel approach to target a subset of aggressive, basal-like 
breast cancers.  
Understanding the genetic and epigenetic abnormalities that are associated with 
breast cancer subtypes will help identify novel subtype-specific targets for therapy. 
These findings add significant information to the genomic and transcriptomic profiles of 
histone lysine methyltransferases and demethylases in different breast cancer 
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subtypes. Indeed, breast cancer subtypes show distinct copy number alteration patterns 
and differential expression for each demethylase gene. These findings add layers of 
information to the genomic and transcriptomic profiles of the KDM4 subfamily in 
different subtypes of breast cancer. These results also lay the foundation for future 
studies to pre-clinically validate histone lysine demethylase inhibition as a therapeutic 
strategy for different subtypes of breast cancer.  
As the most commonly diagnosed neoplasm among women in the United States, 
there exists a critical need for novel insights into the molecular underpinnings of breast 
cancer.8 Together, these findings translate molecular and pathological findings into 
potential clinical benefits for breast cancer patients by understanding the 
clinicopathology and molecular precursors underlying benign breast and breast cancer 
lesions to provide insight into breast tumorigenesis. 
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Despite converging incidence rates for breast cancers by race, disparities in 
mortality persist where black women suffer from poorer prognosis compared to white 
counterparts. To understand the clinical, demographic, and molecular characteristics 
underlying these disparities, we examined differences among patients with breast 
cancer to understand the role of human epidermal growth factor receptor 2 (HER2) 
status, age, and race/ethnicity among women diagnosed with hormone receptor-positive 
breast cancer, and disparities in surgical therapy among female patients with early 
stage young-onset breast cancer. Benign breast disease, another known risk factor for 
breast cancer, includes a histological spectrum of lesions, could contribute to disparities 
in survival among both black and white women is benign breast disease as little is 
known about benign breast tissue from black women. To better characterize the risk of 
breast cancer among black women with benign breast disease, we profiled the 
clinicopathology and molecular characteristics of benign breast lesions among black 
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women who subsequently developed breast cancer. Using the metropolitan Detroit 
benign breast disease cohort, we identified black women with benign breast lesions 
subsequently diagnosed with breast cancer. Gene expression profiling of benign breast 
disease tissue and Cox proportional hazards modeling were used to evaluate 
transcriptional variations associated with time to breast cancer. 1,802 genes were 
significantly associated with a shorter time to breast cancer diagnosis. The greatest 
transcriptional variation associated with time to diagnosis was histone lysine 
demethylase 4C (KDM4C), a histone-modifying enzyme. Given that information 
regarding the genomic and transcriptomic alterations of KDM4C and the KDM4 
subfamily in different subtypes of breast cancer remains largely incomplete, we 
conducted a meta-analysis of KDM4A-D in breast cancer and identified associations 
among recurrent copy number alterations, gene expression, and breast cancer 
subtypes. We demonstrated that KDM4C amplification and overexpression was 
observed in aggressive, basal-like breast cancer tissues. Inflammatory disease ranked 
as the top disorder, and nearly a fifth of the genes classified in the estrogen 
biosynthesis pathway were significantly associated with time to breast cancer. Taken 
together, our findings identify molecular precursors for time to cancer among black 
women with benign breast disease. These results identify increased expression of 
critical molecular determinants, including KDM4C, and pathways that are significantly 
associated with shorter time to subsequent breast cancer development among black 
women. Further studies to better characterize the molecular profiles of benign breast 
and breast cancer lesions can lead to development of molecular classifiers for breast 
cancer risk and diagnosis among black women with benign breast lesions. 
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